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Molecular Imaging (MI) is a growing research discipline that can be defined as 
the in vivo characterization and measurement of biologic processes at the 
cellular and molecular level. Molecular approaches to diagnostics were 
developed few years ago and they have become available to detect diseases 
only recently. Molecular Imaging relies on molecular changes because they 
represent early indicators of pathologies before the latter reach a macroscopic 
level (Figure 1). In this emergent area of research it is mandatory to anticipate 
the time to detect molecular or cellular changes, into the body, to predict as 
soon as possible the disease (1, 2).  
Molecular Imaging finds a huge variety of applications, not limited only to 
detection of a disease in a early stage. Angiogenesis, for example, is a normal 
process that develops naturally during embryonic development or the female 
reproductive cycle, etc.; nevertheless, the vascular growth can happen in an 
unrestrained way determining pathologic conditions. Loss of this regulation is 
known to occur in more than 30 different diseases, e.g.: cancer, cardiovascular 
and  immunologic disease, diabetes, etc., and can be detected by MI. The latter 
can be used to locate apoptosis phenomena. Apoptosys is a physiologic process 
consisting in a programmed cell death. Perturbation of this equilibrium can be 
related to a huge variety of pathologies. Apoptosys reduction can be related to 
cancer, autoimmune diseases, and viral infections. An increase in apoptosys can 
be related to AIDS, neurodegenerative disorders, ischemia, stroke, 




Several instrumental imaging techniques are used to detect molecular changes 
in living organisms tissues. The most common are: 
i) Nuclear techniques, as Positron Emission Tomography (PET), Single Photon 
Emission Computed Tomography (SPECT),  
ii) MR techniques, as Nuclear Magnetic Resonance Imaging (NMRI), Magnetic 
Resonance Tomography (MRT), Magnetic Resonance Spectroscopy 
iii) Optical techniques, as Optical Tomography, Surface Weighted Imaging 
(reflectance diffuse tomography), Phase-array Detection, Confocal Imaging, 
Multiphoton Imaging, or Microscopic Imaging 
iv) Acoustic techniques: Ultrasonography (US) and Photoacoustic Imaging 
In addition to the above cited techniques, hyphenated ones are available where a 
suitable combination of two of them (e.g.: PET-MRI) allow to obtain images 
endowed with an higher degree of diagnostic information. 
Figure 1 
 
Figure 1 shows the different degree of diagnostic information associated with 
the single imaging technique, ultimately related to their resolution. For example 
X-Ray Computed Tomography, as Ultrasounds, allow to appreciate the 
anatomic structure of tissues while Magnetic Resonance Imaging, Nuclear 
Magnetic Resonance Imaging, Optical Imaging or Nanosensors, having a 
higher resolution, are able to give diagnostic informations ranging from 








Optical Imaging encompasses several imaging modalities that can be applied to 
the diagnostic medical field to detect pathological changes in a non-invasive 
way, employing different kinds of “light” (UV, visible and IR). Processes can 
be investigated with Optical Imaging at several levels, at the organ, tissue, 
cellular and molecular one. The image, that derives from optical techniques, is 
produced by the interaction of different forms of light, depending on which 
technique is used. In particular, the image depends on the wavelength of the 
light that is used, from the instrument optical configuration employed to detect 
the signal and from auxiliary  imaging agents used to give the contrast; the main 
limitation of OI is just related to the depth of penetration of light, ranging from 
< 1 mm for UV radiation to some centimeters for IR photons. When light 
interacts with tissues, the latter are involved in three processes: absorption, 
photon scattering and the generation of fluorescence emission (4). These three 
phenomena, on which is based Optical Imaging, are useful to recognize 
different tissues either functionally, for example to detect hemoglobin 
concentration, or structurally, e.g.: cellular morphology. The different Optical 
Imaging techniques are really a lot and generally they are based on the use of 
visible, ultraviolet and infrared light, absorbed, emitted or scattered by 
molecules of cells and tissues. Usually the techniques can be classified into 
Diffuse Optical Tomography (DOT) and Ballistic Optical Imaging (BOI), 
depending from principles are used to obtain the image (5). A special interest is 




dyes are used and if excitation in the IR region is adopted it is possible to 
perform in vivo imaging on whole small animals. A current limitation of this 
technique is the translation from animals to patients, as it means that for 
patients, for example, bulk tissues should not exceed in size over 10 cm (6). 
Optical imaging may be combined with different techniques to have more 
detailed images, as for example OI/MRI (7). 
Exogenous imaging agents such as fluorescent dyes are used in Optical 
Imaging. Thousands of fluorescent dyes are known and some of them currently 
used in fluorescent imaging applications. Indocyanine green (ICG) is approved 
for in vivo use. Cyanines represent the largest family of fluorescent dyes and 
many hydrophilic or conjugated derivatives of cyanines have been synthesized 
to visualize e.g. tumor cells (8, 9). Rhodamine and fluorescein derivatives have 
been extensively employed and conjugated with small molecules acting as 
vectors to detect specifically tumor cells (10). Fluorescent sensors are also 
available for metal ions, changing their emission propertied in the presence of 
different concentrations of specific metal ions (for example Cu2+) and being 
extremely useful for in vivo imaging applications. AlexaFluor® is another class 
of fluorescent dyes, widely used in virtue of the high intensity of fluorescence 
of these derivatives. Finally, the acronym BODIPY includes a class of 
fluorescent dyes where the core structure is represented by 4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene; this unusual heteropolycyclic structure is characterized 
by a very high quantum yield (11).  
 
Positron Emission Tomography (PET) 
 
PET is a diagnostic technique in which images are obtained using the positron 




radionuclides, emittes positrons that annihilates with nearby electrons, emitting 
two collinear opposite γ-rays. An array of detectors collect the radiation, 
discriminating the γ-rays pair emitted by the radionuclide on the base of their 
simultaneous detection an reconstructing the emission source point by 
retroprojecting their trajectories. Several positron emitting radionuclide are 
available, among them light atoms such carbon and fluorine and radiometals 
such as copper and gallium. Some of these elements are present into 
biomolecules into the body, and, this means that the use of positron emitting 
isotopes does not alter the physicochemical and biochemical properties with 
respect to the nonlabeled compounds (12). In PET applications, scientists prefer 
to use 18F, in view of its availability, easy introduction in organic molecules and 
favourable emission energy. Its half-life, of 110 min, is compatible with 3-4 
synthetic steps to be used to prepare labeled organic compounds. One of the 
most used PET agents is 2-[18F]-fluoro-deoxy-D-glucose, also known like 18F-
FDG; it is used to monitor glucose metabolism and it is really important for 
clinical diagnosis of tumors, considering that tumoral cells are quite hungry of 
sugars. 11C is another important positron-emitting isotope and it is less used to 
prepare organic compounds due to the short half-life of 20.3 min. 
In addition to 11C and 19F, several metal isotopes find an application into PET-
imaging, as 64Cu, 76Br, 68Ga and that they are most of all used to study 
biochemical processes connected with slow pharmacokinetics (13). 
PET imaging finds many diagnostic applications and it is best suited for 
detecting some kind of tumors, even if it is becoming a powerful tool in MI 
applications due to its relevant sensitivity. For example it is used to study the 
expression of somatostatin receptors, the latter being involved in: CNS, 
hypothalamopituitary system, gastrointestinal tract, exo- and endocrine 




because it can be involved in neurological and psychiatric disorders, as for 
example Alzheimer’s and Parkinson’s disease (14). 
 
Single-Photon Emission Computed Tomography 
(SPECT) 
 
Single-photon emission computed tomography (SPECT), together with PET 
imaging, was the first imaging modality used in clinical. For SPECT imaging, 
contrast agents are labelled with specific radionuclides, all able to emit γ rays. 
The energy arising in the form of radiation from these radionuclides, have to be 
in the range 100-250 keV to obtain good-quality images. The γ-rays used to 
create the images, are captured by detectors included into a so called “γ 
camera”, and sent to an elaborator dedicated to the image reconstruction and 
editing. Many metal isotopes emit γ-rays useful for SPECT, as 67Cu, 67Ga, 111In, 
90Y, 201Tl, and their corresponding ions may be combined with suitable 
chelating agents to create γ-emitting complexes, to be conjugated with peptides, 
antibodies or other targeting vectors (15). Nevertheless, the most important 
element used for SPECT imaging is 99mTc, because when it emits γ rays, the 
energy released is of 140 keV (89% abundance), meaning that this element is 
perfect to be detected in imaging with a gamma camera. A drawback of using 
99mTc is its relatively short half-life, about 6 h, hampering long and articulate 
preparations, but compensated by the availability of this nuclide through a 
dedicated generator. Nowadays applications with 99mTc can offer two 
possibilities to exploit this element, it means that it can be used to label a 





Radiopharmaceuticals containing 99mTc are used to study many diseases: 99mTc-
diphosphonate radiopharmaceuticals are accumulated into bones, and this is 
important to detect bone metastases or hidden fractures. 99mTc-D,L-HM-PAO 
(Ceretec) and 99mTc-LL-ECD (Neurolite) for example allow to study blood flow 
into the brain, while 99mTc-sestamibi (Cardiolite) gives informations both for 
myocardial perfusion imaging and also for cancer imaging (16). Cu2+ has a rich 
coordination chemistry exploited to in a large variety of complexes with 
nitrogen-based ligands, including cyclen and cyclam derivatives. Considering 
that coordination numbers of this element range from 4 to 6, geometries of 
several Cu2+-complexes can be square planar, square pyramidal, trigonal 
bipyramidal, and octahedral (17, 18). Several 67Cu2+-complexes were studied 
for SPECT detection of tumors (19, 20). 67Ga3+ recently received renewed 
interest for the preparation of chelates for SPECT due to the availability of this 
nuclide through a dedicated generator. Many derivatives have been reported in 
the scientific literature, mainly concentrated on hexacoordinated ligands that 
can match the coordination requirements of this “hard” trivalent ion (21). 
SPECT was extensively employed in Molecular Imaging application, such as 
the sensitive detection of: folate receptors and oxytocin receptor that are 
generally over-expressed on tumoral cells, or integrins receptors, directly 






X-Ray Computed Tomography (x-ray CT) 
 
X-ray-computed tomography (CT) is a technique that allows to obtain three-
dimensional images of tissues and screening diseases into a non invasively way.  
CT is a relatively old technique, having become a diagnostic tool when X-rays 
were discovered in 1895. Electromagnetic radiation of X-rays has wavelengths 
within the range of 0.01 and 10 nm. X-rays are generated in a vacuum tube 
where electrons are accelerated and travel from a catode to a tungsten-alloy 
anode; colliding with the anode electrons are braked, releasing X-rays with a 
specific energy dependent from the energy of incident electrons. CT is 
extremely versatile: gastrointestinal tract, cardiovascular system, renal tract, 
liver, lungs, bone, cartilage and some tumor tissues can be screened by this 
technique (25). Diagnostic images are formed by the absorption of X-rays from 
heavy atoms present in the tissue such as calcium. During CT contrast agents 
may be used; they generally contain atoms with an high atomic number, as I or 
Ba as the latter strongly absorb X-rays, and are employed to improve imaging 
of soft tissues. 
Contrast agents based on iodine can be ionic or nonionic molecules usually 
belonging to the class of 2,4,6-triiodoarylcarboxamides. Ionic compounds are 
inclined to interact with biological molecules, as peptides or cell membranes, 
and may increase the plasma osmolality due to the large dose administered (26). 
For this reason generally nonionic contrast agents are preferred to the charged 
ones, even if nowadays both of them have been improved thanks to their 
manipulation, for example adding hydrophilic residues that allows higher 
solubility in water and lower toxicity (27). Among iodine contrast agents, the 
most used in CT are iopamidol, iomeprol, iohexol, iopromide. Barium sulfate, 




triiodoaromatics (28, 29). A recently described Ca++-based comtrast agent 
offers the possibility to study the biochemical state of a tissue, like for example 
bone or cartilage (30), exemplifying the use of X-ray CT in MI applications. 
 
Ultrasounds echography (US) 
 
Ultrasounds found a broad practical application in clinical diagnostics in virtue 
to their useful properties. Ultrasound echography is a relatively cheap technique 
giving the possibility to detect pathologies without relying on ionizing 
radiations like X-rays and γ-rays; in addition images are obtained in real time. 
This technique provides defined images of organs, for example hearth chambers 
and generally images of anatomical structures (e.g. fallopian tubes). Contrast 
agents, employed in this technique have to be able to reflect and scatter 
ultrasounds waves and to be necessary biocompatible.  
Contrast agents used for ultrasounds are composed of microbubbles with a 
diameter in average of 1-7 µm. These can be used as tracers to study 
pathologies into the liver for example, like cirrhosis and metastases (31). The 
preparation of microbubbles generally is done into a biocompatible liquid, e.g.: 
saline or viscous dextrose or X-ray contrast solutions. The pulse of ultrasound 
excites the gas microbubble, and, in this way, thanks to the vibration of the 
bubble, secondary ultrasound waves are emitted with different intensities. 
Finally the reflectance of microbubbles provides a bright contrast. US images 
are exploited for echocardiography, Doppler macrovasculature, and Doppler 
microvasculature, depending on the area of interest and on the specific 
diagnostic need (32). The fluid employed to form microbubbles for US can be 
air, nitrogen, sulfur hexafluoride or perfluorocarbons such as perfluorooctane. 




within microbubbles, and contribute to their stabilization. The first microbubble 
containing perfluorooctyl bromide (C8F17Br) conferred to emulsions a 
significant lipophilicity, so that it was used to study the gastrointestinal tract. 
SF6 microbubbles, instead, are made of lyophilized phospholipids/polyethylene 
glycol/palmitic acid powder stored under SF6 gas (33) and is used to detect liver 
lesions otherwise difficult to observe. Nevertheless, microbubbles result useful 
to detect many pathologies, as diseases of the heart, vascular structures, liver, 
breast, spleen, pancreas (cystic pancreatic masses with a different 
vascularization pattern) and gastrointestinal tract (Crohn’s disease with a 
thickened bowel wall) (34-36). Targeted microbubbles are in development, in 
which specific molecules are included in the bubble external surface in order to 
direct them preferentially into tissues of interest, with a focused increase of the 
echogenic signal. 
 
Magnetic Resonance Imaging (MRI) 
 
Magnetic Resonance Imaging includes different techniques engaged to detect 
diseases at different levels: anatomical, physiological, metabolic and molecular. 
Thanks to the development of NMR techniques declined in clinical diagnostic 
modalities, a new class of pharmaceuticals, the MRI contrast agents (CAs) was 
developed. CAs are injected to a patient to enhance the image contrast between 
normal and diseased tissue and/or to indicate the status of organ function or 
blood flow. The image intensity in 'H NMR imaging, largely composed of the 
NMR signal of water protons, is dependent on nuclear relaxation times. 
Complexes of paramagnetic transition and lanthanide ions, which can decrease 
the relaxation times of nearby nuclei via dipolar interactions, have received the 




1H-NMR image intensity depends on relaxation times of protons in body 
tissues. In this technique, one or more radiofrequency pulses are used to 
perturbe the net macroscopic magnetization of proton spins, where the latter 
result aligned in a parallel way along the z axis with the applied field. The 
component of the magnetization, after being perturbed by the external field, 
from the z axis ‘relaxes’ back from its equilibrium value in an exponential way. 
This exponential time constant is called the longitudinal (or spin-lattice) 
relaxation time and it is indicated with TI. Also the transverse magnetization 
decays coming back to its equilibrium value of zero, where the time dependence 
of the magnetization perpendicular to the z axis is called the transverse (or spin-
spin) relaxation time, that is T2. Generally, when acquiring NMR image data, 
many pulses are rapidly repeated and relaxation strongly affect the signal 
intensity due to its direct influence on magnetization recovery. Moreover, 
tissues with short T1, give images with a greater intensity if they are compared 
to tissues with longer T1 values, because the steady-state magnetization along 
the z axis is better recovered in the tissue with the fastest relaxation. Instead, if 
we consider T2 constant, short values of this parameter are generally associated 
with a lower signal intensity, because the net transverse magnetization, that is 
important to detect the signal, is lower too (37, 38). The main purpose of NMR 
is to enhance the proton relaxation rate of water, ability known as relaxivity, to 
increase, finally, in a significant way, the relaxation rate of tissues of interest. 
This is possible using complexes with paramagnetic metals that exchange 
rapidly their coordinated water with the bulk water; the proton of coordinated 
water molecules relax very fast, and the fast exchange allows to spread the 
relaxation effect to the water molecules of the bulk solution. MRI CAs have to 
be non toxic, hence an outstanding thermodynamic and kinetic stability of the 
metal complexes is strictly required. The minimal dose, to produce relevant 




detected by NMR imaging, and for the currently used Gd-complexes is about 
0.1 mmol/Kg. 
The diamagnetic and paramagnetic contributions to the relaxation rates of such 
solutions are additive and given by eq 1, where (l/Ti)obsd is the observed solvent 
relaxation rate in the presence of a paramagnetic species, (1/Ti)d is the 
(diamagnetic) solvent relaxation rate in the absence of a paramagnetic species, 
and (1/Ti)p represents the additional paramagnetic contribution. 
 
(1/Ti)obsd = (1/Ti)d + (l/Ti)p         i = 1, 2 (1) 
 
If there are no solute-solute interactions, relaxation rates of the solvent become 
linearly dependent on the concentration of the paramagnetic species ([M]); 
relaxivity, ri, is the slope of this dependence and it’s expressed in units of M
-l s-l 
or, more commonly, mM -l s-l (eq 2). 
 
(l/Ti)obsd = (1/Ti)d + ri[M]       i = 1, 2       (2) 
 
 
The magnetic field right around the paramagnetic center, given its large and 
fluctuating nature, gives an additional relaxation pathway for solvent nuclei. 
Far from the paramagnetic center, these fields decrease suddenly, molecules of 
the solvent and of the complex start to have random translational diffusion and 
specific chemical interaction; this means that solvent molecules wander around 
the metal ion, arriving at a distance enough to transmit the paramagnetic effect 
(e.g.: within 5 Å). 
The sum of these contributions gives the total relaxivity of the paramagnetic 
species. Relevant contributions to water proton relaxivity, may be ascribed to 







In the first mechanism (A) the interaction between the water molecule and the 
metal ion happens in its first coordination sphere, followed by the water 
molecule exchange with the bulk solvent. This is a relaxation mechanism that is 
called “inner-sphere relaxation”. This behavior happens in the same way also 
for the case B, but the interaction, that is with hydrogen-bonded waters, 
involves the second coordination sphere. The mechanism of the second 
coordination sphere interactions is complex and not completely clarified; 
moreover it is not always possible to distinguish this relaxation mechanism 
(type B) from the type C, i.e.: translational diffusion of the water molecule 
around the chelate, referring simply to “outer-sphere relaxation”. The total 
relaxivity of a paramagnetic agent is therefore generally given by eq 3. 
 
(l/Ti)p = (l/Ti)inner sphere + (l/Ti)outer sphere i = 1, 2 (3) 
 
 
The inner sphere mechanism involves a chemical exchange of the water  
molecule between the primary coordination sphere of the paramagnetic metal 







PM is the mole fraction of metal ion, q is the number of water molecules bound 
per metal ion, T1M is the relaxation time of the bound water protons, and τM  is 
the residence lifetime of the bound water. 
The correlation times τC and τE, as given by eq 6 and 7, regulate the dipolar and 






T1e, is the longitudinal electron spin relaxation time, τM is the water residence 
time and τR is the rotational correlation time of the entire paramagnetic (metal-
water) assembly. The rotational correlation time is a parameter whose variation 
lead to remarkable effect on the relaxivity; for this reason the research of this 
PhD has been focused on nanosystems, where the increase in the size of the 
paramagnetic system is immediately reflected in the reduction of its tumbling 







Nanostructures for Diagnostic Applications 
 
Nanostructures, are systems composed of atoms or molecules of few units till to 
thousands ones with dimensions of the order of nanometers. Depending on 
dimensions, nanostructures can be classified in different classes: nanofabrics 
where the range of the height varies from 0.1 to 100 nm while the depth and 
width are bigger than nanometer dimensions; nanotubes, like carbon nanotubes, 
present a nanometric diameter and nanoparticles that have all three dimensions, 
height, depth and width, of the order of nanometers. To understand the order of 
magnitude of such particles, it should be noted that the wavelength of photons 
in the visible spectrum, is much longer than the diameter of the largest 
nanoparticle. Special instruments can be used to study nanoparticles, such as 
electron microscopes, or soft and hard X-rays, the use of which, however, is 
much more complex. 
The study of nanosized systems began in the eighties to understand the behavior 
of matter at the mesoscopic level as it is an important link between the 
macroscopic matter, whose properties are described by thermodynamics and 
statistical mechanics, and the microscopic matter (the single atom or molecule). 
This is important because nanosized systems have some properties that are not 
showed in macroscopic systems, like transition from van der Waals bonding to 
metallic bonding in clusters of mercury; transition from paramagnetic to 
ferromagnetic behavior that has totally disregarded the prior knowledge on the 
magnetic properties of certain materials; interface between liquid and nanosized 
solid that presents many interesting aspects about the melting points and the 
nature of metastable phases, stages and sub-cooled overheated. 
Commonly defined nanoparticle vectors include: liposomes, micelles, 




nanoparticles and polymeric nanoparticles, although the scope of nanoparticle 
formulations that have been applied to cancer therapy is far more elaborate (40, 
41). 
Depending on the chemical composition of the nanoparticles, they can carry a 
wide variety of compounds, making them efficient drug delivery vehicles. 
Polymers, dendrimers and lipidic nanosystems represent three-dimensional 
networks that form the matrix system and this one is used to encapsulate active 
principles. Several kinds of drug vectors have been investigating to increase 
specificity and activity for drug delivery systems and at the same time to reduce 
toxicity ensuring maximum treatment safety. 
Many active pharmaceuticals ingredients (APIs) are not capable to cross the 
biological barriers that separate the administration site from the site of action 
due to physicochemical characteristics, while their inclusion in a nanosized 
system may represent an alternative pathway to enter the target site. 
Sometimes APIs collide with enzymatic barriers, which lead to their 
degradation and fast metabolization. Therefore these active molecules can 
difficulty distribute themselves into the diseased target zones and may 
accumulate themselves in healthy tissues leading to unwanted toxic effects. 
Inclusion in a nanosized system may efficiently shield the API from the 
degradative activities of metabolic enzymes. 
In addition, installation on the surface of the nanosystem of highly specific 
vectors lead to the delivery of the API to to the desired action site. Carriers of 
this type for drug delivery were created in the last twenty years and new 
medicines are developed to be delivered by matrix or vesicular carriers, such as 
doxil, where the drug is inside the liposomes is used for cancer treatment, or 











Figure 2: Nanosized systems employed in Molecular Imaging. 
 
Micelles are aggregates of amphiphilic molecules in which the polar head 
groups are in contact with water while the hydrophobic moieties are located in 
the particle core to minimize their contact with water. In non-polar solvent the 
orientation is reversed and the micelle is called “reverse micelle”. Micelles can 
assemble in different shapes, such as spherical, cylindrical, lamellar and disk-
shaped. Micelles can form above the critical micelle concentration (CMC) and 




dynamic structure because there is a continuous exchange between micelles and 
the aqueous solution.  
Generally it is possible to modify the surface of the original mixture of micelle-
forming surfactants adding new co-surfactants and also size and charge of these 
systems according always to the molecule that has to be transported (43). 
It is really common to use PEG surface modification to avoid uptake by the 
reticuloendothelial system and mononuclear phagocytes, obtaining in this way 
stealth-shielded nanoparticles (44). There are also polymeric micelles that are 
generally more stable than surfactant micelles, and form at markedly lower 
CMCs. These are less dynamic than those formed from surfactants and it has 
been demonstrated that if free polymers are separated from polymers forming 
micelles they are still stable even if CMC decreases (45). 
One or several phospholipid bilayers can auto-associate among themselves to 
form liposomes, leaving an aqueous compartment inside the structure. This 
structure is strongly similar to cell membranes and has been the subject of study 
of many research groups in chemistry, biophysics and pharmaceutics. 
Liposomes for their composition and also for the preparation method can 
present different features. Liposomes are usually prepared in simple multi-step 
operations:  
• dissolution of the lipids in an organic solvent 
• solvent evaporation 
• dispersion of the dried lipids in an aqueous solution 
The main differences can arise on the method used to disperse the dried lipids: 
lipid dispersion can be obtained by hydration of the phospholipid film, 
sonication, microfluidification, extrusion, reverse-phase evaporation, ether 
infusion, injection of an ethanol solution, freeze-drying/rehydration, 




characteristics depend on the preparation technique and in this way the main 
size of these supramolecular structures can be from tens to a hundred 
micrometers. The number of lipidic bilayers can vary so that liposomes can be 
classified into: MLV (Multilamellar Vesicles) present a diameter more than 0.5 
µm, UV (Unilamellar Vesicles) with a diameter more than 1 µm and MVV 
(Multi Vesicular Vesicles) with a diameter more than 1 µm and many vesicles 
inside the liposome. Unilamellar vesicles can be divided into three subclasses: 
SUV (Small Unilamellar Vesicles), with a diameter between 20 and 100 nm, 
LUV (Large Unilamellar Vesicles), with diameters above 100 nm, GUV (Giant 
Unilamellar Vesicles), with diameters above 1 mm (46). 
These lipidic supramolecular systems are endowed with several advantages, and 
have been used as a vector for drugs. Moreover they are able to include both 
hydrophobic compounds, anchored into the bilayer, or hydrophilic substances, 
encapsulated in their cavity. 
The passive encapsulation technique consists to rehydrate the lipidic film in the 
presence of the active substance (47), while the active process is applied after 
having made liposome using a concentration or pH gradient and it consists to 
mix hydrophobic drugs with phospholipids before the formation of the lipidic 
film (48, 49). 
Solid lipid nanoparticles (SLN) are made generally of glycerides and present a 
diameter that can vary from 50 to 1000 nm. These nanoparticles can be 
obtained by different methods as high pressure homogenization, 
microemulsion, nanoprecipitation, where crystallinity of lipids can be different 
and the degree of this depends on the method which is used to product SLNs. 
The technique chosen to prepare SLNs is important because crystalline 
polymorphism defines the colloidal stability of these systems (50). 
Nanoparticles can be constituted by metals or metal oxides for use as MRI 




investigated for their properties of superparamagnetism as maghemite (γ-Fe2O3) 
and magnetite (Fe3O4). Superparamagnetism is a really important property that 
allows for stability and individual dispersion of the particles after that an 
external magnetic field has been removed (51). Another class of metal 
nanoparticles are gold-nanoshells where there is an external Au-coating around 
a silica core, giving them a favourable use as contrast agents in optical 
coherence tomography, because variations in their size and shape allows for the 
precise tuning of their resonance wavelength (52). 
Dendrimers are molecules composed of monomers with a central 
plurifunctional core and a tree-like growth process around. Due to their large 
number of surface groups and monodispersity, dendrimers have the ability to 
create multivalent interactions leading to their efficient use as vectors (53). 
Polymers are large molecules composed of many repeated subunits. Polymers, 
both natural and synthetic, are created via polymerization of many monomers 
and so their consequently large molecular mass relative to small molecule 
compounds produces unique physical properties. Moreover incorporating 
inorganic nanostructures into a polymer matrix, the properties of both materials 
can be synergistically combined to create new attributes. 
Metal-organic frameworks (MOFs) are also known as coordination polymers 
and they consist into an hybrid system made of metal connecting points and 
organic bridging ligands (54, 55). In the structure of MOFs bridging ligands can 
connect either metal ions or small metal clusters. These systems show really 
interesting properties, mainly due to their wide porosity with tunable pore sizes, 
shapes and functionalities. High agent loadings through several methods (direct 
incorporation into the framework or post-synthetic modification), intrinsic 
biodegradability from labile metal-ligand bonds, high porosity for 
loading/release of entrapped agents, and versatile functionalization 
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Outline of the thesis 
 
The PhD research activity was devoted to explore original nanosystems for 
Molecular Imaging diagnostic applications. In this wide area of research, the 
activity of all three years was focused on the design, the preparation and the 
testing of novel and improved components for nanosized CAs for MRI. 
The choice of MRI resides in its enormous potential in Molecular Imaging 
applications, where the superior resolution attainable led to extensive use of this 
diagnostic technique. The research group in which this PhD work was carried 
out has nearly 20 years of experience in MRI CAs, and the collaborations 
established in this period allow to perform a comprehensive and detailed 
evaluation of the compounds synthesized. 
While resolution of MRI images is already very high, its sensitivity is far from 
optimal, suffering from the need for a significant concentration of paramagnetic 
species in order to obtain a suitable contrast efficiency. At least 107-108 
molecules are needed to clearly visualize one cell, compared to the 102-103 
molecules/cell required for Optical Imaging and the 100-101 molecules/cell 
needed for visualization with PET/SPECT techniques.  
Nanosized systems are especially suited to solve the sensitivity problems, as a 
single nanometric assembly used as a container can deliver several thousands 
CA molecules at a time. In addition, the nanosystem can be easily decorated 
with vector molecules, addressed to its targeting to specific cells or tissues, and 
with auxiliary components dedicated to the tailoring of its physical, chemical 
and biologic properties or to modify the nanoparticle behaviour. For example, 
nanoparticle coating with PEG or other hydrophilic appendages lead to an 
improvement of both solubility and plasmatic half-life, helping and extending 




This thesis reports the results of three different activities carried out during the 
PhD period and summarized as follows: 
1) Design, synthesis and testing of three original amphiphilic MRI CAs, based 
on Mn2+-complexes of novel lipophilic derivatives of the well know ligand 
EDTA. These amphiphilic chelates are included in the formulation of 
supramolecular lipid-based aggregates (micelles, liposomes, serum-albumin 
non-covalent conjugates), where they play an active role as contrast agents. 
2) A unimolecular nanosized chelating agent is prepared by functionalization of 
polyethyleneimine with phosphonic groups. The loading of this polymeric 
chelating agent with Gd3+ ions leads to a paramagnetic nanosized system; 
relaxometric investigations on this system was undertaken to evaluate its 
potential as MRI contrast agent. The paramagnetic polynuclear complex is not 
intended as a component of a larger nanosized Molecular Imaging probe, rather 
it represents as such a complete MRI CA, containing and transporting several 
paramagnetic metal ions in a compact molecule of the desired nanometric size. 
3) The synthetic activity of the PhD project involved the preparation of several 
different compounds, the latter being usually represented by polyamine-based 
chelating agents and their synthetic precursors. In view of the fact that most of 
these compounds will be employed in vivo, preliminary examination of their 
toxicity is routinely and periodically performed on the compounds prepared. 
During this screening, a biological activity was noticed for a family of diamines 
employed for the synthesis of chelating agents for Mn2+, and found to be related 
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In the field of MRI contrast agents (CAs) amphiphilic paramagnetic complexes 
are usually endowed with increased plasmatic half-life and high relaxivity 
values, but limited examples of amphiphilic Mn(II)-based CAs have been 
reported to date. In this work the Mn(II)-complexes of three original 
amphiphilic ligands derived from the well known EDTA and embodying 
one/two aliphatic chains were evaluated as potential MRI contrast agents and 
compared. Strong self-association to micelles and binding to serum albumin 
brought observed relaxivities to significantly high values and confirm the 
possibility to use supramolecular assemblies based on amphiphilic Mn(II)-










MRI contrast agents (CAs) are paramagnetic complexes employed to increase 
the relaxation rate of the observed nuclei (mainly 1H), allowing better 
diagnostic images to be acquired in a shorter period (1). Gadolinium based CAs 
are currently employed in clinical MRI due to the large paramagnetism showed 
by the f7-lanthanide ion (2). Recent reports on the insurgence of pathologies 
associated to the release of Gd(III) ions in nephropathic patients, relived the 
interest in CAs based on different metal ions (3). Mn(II) represents a promising 
alternative (4): although magnetic properties are lower than those of Gd(III), it 
is an essential endogenous element and its eventual release in trace in vivo 
could be more easily managed by the organism. In addition, it is cheap and 
widely available. In the field of MRI CAs, amphiphilic paramagnetic 
complexes are usually studied in virtue of their increased plasmatic half-life and 
high relaxivity values, the latter being usually observed when the CAs are 
tightly bound to macromolecular or supramolecular systems as lipid-based 
formulations (5). Suitably designed lipophilic CAs can reach relaxivity values 
up to 90 mM-1s-1 (6) compared to the values in the range 3-5 mM-1s-1 showed by 
currently used “hydrophilic” CAs. While a large number of lipophilic Gd-based 
CAs were studied in the last two decades and summarized in recent reviews (7), 
scarce reports of lipophilic Mn-based CAs may be found in the scientific 
literature. Inclusion of the Mn(II)-complex of DTPA bis(stearylamide) in small 
unilamellar liposomes are the first example, dating back to 1989-90 (8); 
nevertheless, this system and the cognate EDTA-oleyl ester (9) recent analog 
represent preliminary approaches where stability issues were not tackled. Large 
non-hydrophilic appendages were later implanted on the backbone of the EDTA 




blood-pool CAs with a significant improvement of the observed relaxivities 
(10, 11). 
Almost all chelating agents employed for the formation of Gd(III) or Mn(II) 
complexes for clinical MRI applications may be classified in two families, i.e. 
acyclic and macrocyclic polyamino-polycarboxylates (12-17). As Mn-based 
CAs are usually endowed with lower relaxivity values compared to the 
corresponding Gd-based CAs, we were prompted to explore the possibility to 
boost their relaxometric properties by taking advantage of the formation of 
lipidic aggregates. To this purpose, three different ligands were synthesized, 
choosing the hexadentate ligands EDTA as preferred scaffold (Figure 1). The 
Mn(II) complexes of these newly synthesised ligands were prepared and studied 
by relaxometric techniques in both their aggregated form and in their 
























Results and Discussion 
 
Ligands design  
Several examples of Mn(II)-complexes with penta- or hexa-dentate 
polyaminopolycarboxylate ligands have been recently reported with the aim to 
form Mn(II)-complexes with the best balance between their thermodynamic and 
kinetic stabilities and the number of inner-sphere water molecules (4). Among 
them, Mn(II)-EDTA-like chelates still represent good systems on which build a 
contrast agent as Mn(II)-EDTA is well tolerated, sufficiently stable and it is has 
a water molecule coordinated to the metal centre (q = 1) (18). Moreover, the 
Mn(II)EDTA complex has the great advantage to be endowed with a water 
exchange rate (kex) close to an optimum value for a contrast agent (4.7 × 10
8 s-1 
at 25°C). The latter property is fundamental to reach high relaxivity values once 
the Mn(II) complex is in a slowly tumbling form with long τR i.e. when it is in 
aggregated form or bound to serum albumin.  
Lipophilic EDTA derivatives were designed by placing one (TDDTA and 
ODDTA) or two (HCDTA) aliphatic straight chains on the central 
ethylenediamine backbone, to reduce any potential steric hindrance with the 
metal coordination sphere. To this end, we considered the recently reported 
approach that used Gd-chelates bearing two aliphatic chains on adjacent 
coordinating arms for the formation of micelles or liposomes with the aim to 
reduce considerably their local rotational motion (19); with this approach, high 
relaxivity values up to 40 mM-1s-1 (298 K, 20 MHz) were obtained for 
liposomes loaded with GdDOTA(GAC12)2. Moreover, it is well known that 
lipidic nanoparticles formed by amphiphilic complexes containing one aliphatic 
chain are not sufficiently stable in vivo giving also a strong haemolytic effect. 




allows a higher stability, a long blood half-life and no haemolytic effect. 
Finally, as also the length of the hydrophobic chain can influence stability, size 
and clearance time of the nanoparticles, twelve and sixteen carbon chains were 
chosen in the synthesised ligands. It is noteworthy that amphiphiles bearing C12 
chains have been recently reported to accelerate considerably the clearance rate 
of liposomes embedding them in the membrane bilayer (20). 
 
Ligands synthesis 
Single chain EDTA derivatives were prepared through a common synthetic 
pathway, depicted in Scheme 1. 1-Tetradecene and 1-octadecene, were 
subjected to bromination with molecular dibromine. The vicinal dibromides 
were converted to the corresponding diamine through sequential conversion to 
the vic-diazide (with NaN3 in DMF) and catalytic transfer hydrogenation (CTH) 
(HCOONH4, Pd/C in refluxing 2-propanol). Conventional per-alkylation with t-
butylbromoacetate/K2CO3 in acetonitrile and t-butyl esters removal with neat 
TFA completes the 5-steps preparation of 1,2-tetradecanediamine-N,N,N’,N’-












Scheme 1: Synthesis of TDDTA and ODDTA. 
 
The third ligand (13,14-hexacosanediamine-N,N,N’,N’-tetraacetic acid) 
(HCDTA) was designed to embody two aliphatic straight chains on the vicinal 
position of the ethylenediamine backbone. For its preparation, a different 
synthetic strategy was devised, reported in Scheme 2. A multicomponent 
condensation of 1H-benzotriazol, glyoxal and dibenzylamine led to a mixed 
diaminal (21), then reacted with 2 equivalents of  dodecylmagnesium bromide 
giving, through a double displacement of the benzotriazole moieties, a 
tetrabenzylated 1,2-didodecylethylenediamine 6. Removal of N-benzyl groups 
is accomplished by CTH to give 13,14-hexacosanediamine 7. The primary 
diamine is tetraalkylated with the combination t-butyl bromoacetate-potassium 
carbonate in acetonitrile generating the tetraester 8, subsequently converted to 






































a    R = C12H25






















































































A detailed relaxometric characterization was undertaken on the Mn(II)-
complexes prepared on the three ligands described in the previous section, in 
order to ascertain their potential as MRI CAs. 
Determination of the relaxivity of the Mn(II)-complexes was at first 
accomplished on dilute solution, in order to measure relaxivity values on the 
monomeric form of amphiphilic complexes, i.e. under the critical micelle 
concentration above which self-aggregation may occur. The complexes Mn(II)-
TDDTA and Mn(II)-ODDTA showed in these conditions relaxivities of 4.7 
mM-1s-1 and 5.9 mM-1s-1, respectively, in good agreement with values expected 
for monomeric Mn(II)-chelate with one coordinated water molecule (q = 1). On 
the other side, the complex Mn(II)-HCDTA shows even in dilute conditions 
evidence of self-association and no cmc values can be determined. The 
relaxivity value of 18.4 mM-1s-1 measured is compatible with a supramolecular 
aggregate even at the lowest concentrations used for relaxivity determination. In 
order to establish the microscopic (supra)molecular parameters that govern the 
relaxivity of the complexes, their 1H NMRD profiles were measured at different 

















Figure 2: NMRD profiles for Mn(II)-TDDTA, Mn(II)-ODDTA, Mn(II)-
HCDTA. 
 
The results reported in Figures 2 clearly show some difference in the behaviour 
of the three paramagnetic species. Mn(II)-TDDTA, bearing a single C12-
aliphatic chain on the ethylenediamine backbone, show a NMRD profile quite 
similar to that observed for the parent EDTA. On the other hand, in the NMR 
profile of the longer chain analog Mn(II)-ODDTA a distinctive broad hump at 
higher fields demonstrate the formation of high-molecular weight paramagnetic 
species, expected in view of the concentration used (>cmc). A sharper and 
higher peak is observed in the NMRD profile of Mn(II)-HCDTA, indicative of 




further supporting the strong propensity of Mn(II)-HCDTA to self-association 
phenomena. 
The NMRD profiles data at three different temperatures allow to extract 
information on the structural dynamics of the paramagnetic complexes. Fitting 
the data by the Solomon-Bloembergen-Morgan theory gives access to the 
parameters that influence the relaxivity, reported in Table 1. 
 
Table 1: Best-fit parameters obtained by analysis of the 1H NMRD profiles for 










-1 s-1)[a] 4.6 5.9 18.4 
∆2 / 1019 s-2 10.7 8.7 1.8 
298τV / ps 23 26 33 
kex
298 / 106 s−1[b] 470 470 470 
298τRG / ns 0.12 0.17 9 
298τRL / ps -- -- 125 
S2 -- -- 0.60 
q 1 1 1 
 
RMnH, a and 
298
D were fixed in the fitting procedure to 2.83 Å, 3.6 Å and 2.3 × 
10-5 cm2 s-1, respectively. [a] 30 MHz; [b] fixed in the fitting procedure. 
 
The fitting shows that the three complexes share a common EDTA-like 
behaviour, with q = 1 and fast exchange rate of the coordinated water molecules 




of the devised application, as the combination of a short lifetime of the 
coordinated water and the raise in the rotational correlation time related to the 
increase in the size of the paramagnetic system lead to very high values of 
relaxivity. Indeed Mn(II)-HCDTA with its significant degree of association in 
these conditions and shows an interesting relaxivity of 18.4 mM-1s-1, with the 
beneficial combination of fast water exchange and slow rotation of the 
paramagnetic system. 
 
Interaction with HSA 
The favourable structural and dynamic features of the EDTA-derived 
amphiphilic complexes pushed us to explore their behaviour in different 
conditions. In particular, investigation of the complexes in the presence of 
human serum albumin (HSA) is of great interest because this 64 KDa protein is 
present in high concentration in blood and its remarkable transport properties 
was shown to be useful for hosting paramagnetic complexes, boosting their 
relaxivity (6). 
Relaxometric titration was then conducted on the three complexes, exposing 
them to increasing concentration of HSA, registering the increase in relaxivity 
consequent to the eventual interaction. 
The results of these titrations are reported in Figure 3, along with the NMRD 
profiles of the complexes in the presence of an excess of HSA registered at two 










Figure 3: Relaxometric titrations with HSA and NMRD profiles for Mn(II)-





The analysis of the combined data from the titrations and the NMRD profiles 
allowed to extract parameters related to the interactions and to the paramagnetic 
system formed by the interactions of the complexes with HSA. 
The results of the fitting of the data according to the SBM theory are reported in 
Table 2. 
 
Table 2: Best-fit parameters obtained by analysis of the 1H NMRD profiles for 















RMnH, a and 
298
D were fixed in the fitting procedure to 2.83 Å, 3.6 Å and 2.3 × 
10-5 cm2 s-1, respectively. [a] 20 MHz; [b] fixed in the fitting procedure. 
 
The results are very interesting as all three paramagnetic complexes efficiently 
interacts with the protein as can be appreciated by the curves of the 











61.5 59.1 48.0 
∆2 / 1019 s-2 0.69 0.6 0.68 
298τV / ps 30 20 24 
kex
298 / 106 s−1 160 160 130 
298τRG / ns 
[b] 40 40 40 
298τRL / ps 880 1200 261 
S2 0.72 0.70 0.66 




paramagnetic systems Mn(II)-complex-HSA, towering in the range 48-61.5 
mM-1s-1; these values are extremely high for this family of CAs, and rarely 
observed even with Gd-complexes. 
The parameters of Table 2 clearly evidence that the huge increase in the 
relaxivity has to be ascribed to the slowed tumbling of the paramagnetic chelate 
as a consequence of the strong interaction with serum albumin, the latter 
hosting the former in one of the possible binding sites. 
Additional work is in progress in order to shed more light on the nature of this 
strong interaction and to test these paramagnetic complexes in the presence of 




In the present work, three amphiphilic ligands derived from the well known 
EDTA are designed and prepared. Two ligands bear a single aliphatic chain 
(C12 and C16), placed on the ethylenediamine central moiety; on the same 
residue of the third ligand are placed in vicinal positions two identical aliphatic 
C12 chains. The Mn(II)-complexes prepared from these ligands show relaxivity 
values of 4.6-5.9 mM-1s-1 for the single-chain derivatives, compatible with an 
EDTA-like behaviour. In contrast, the double-chain derivatives shows higher 
relaxivity values due to self-aggregation even at the lowest concentration 
employed. The presence of HSA to simulate the blood environment brings a 
massive increase in the relaxivity, boosting to 48-61.5 mM-1s-1 as a 
consequence of the strong interaction of the serum protein, hosting the 
paramagnetic complex in a compact assembly. These results shows that Mn(II)-
based CAs may be used to reach high relaxivity, usually ascribed only to Gd-







Solvents and starting materials were purchased from Aldrich, Acros, Fluka and 
Alfa and used without further purification. All water solutions were prepared 
from ultrapure laboratory grade water (18 MΩ·cm) obtained from 
Millipore/MilliQ purification system. 1H NMR spectra were recorded at 300 
MHz with a Jeol Eclipse ECP300 spectrometer. Chemical shifts are reported in 
ppm with the protic impurities of the deuterated solvent as the internal 
reference. Mass spectra were obtained with a Finnigan LCQ-ion trap equipped 
with an electrospray source. TLC and gravimetric chromatography were 
performed with silica gel 60 (MN Kieselgel 60). 
General procedure for the preparation of 1,2-dibromoalkanes 
1-Alkene (1.0eq) was dissolved in dichloromethane (1 M) and bromine (1.05eq) 
was added dropwise to the solution until a stable red colour was obtained. The 
reaction mixture was further stirred at room temperature for 1 h. The solvent 
was removed in vacuo giving 2a-2b as colourless oils, directly used for the 
following step. 
1,2-Dibromododecane (2a) 
Yield 99%.1H-NMR (CDCl3):4.16 (tt, 1H, J = 9.3, 6.8 Hz) 3.84 (dd, 1H, J = 
10.2, 4.4 Hz), 3.61 (t, 1H, J = 9.9 Hz),  2.11-2.06 (m, 1H), 1.88-1.72 (m, 1H), 
1.63-1.19 (m, 20H), 0.88 (bt, 3H, J = 6.6 Hz).13C-NMR (CDCl3): 53.2 (CH), 
36.4 (CH2), 36.1 (CH2), 36.0 (CH2), 29.76 (4xCH2), 29.66 (CH2), 29.51 (CH2), 








Yield 99%. 1H-NMR (CDCl3): 4.15 (m, 1H), 3.83 (dd, 1H, J= 10.1, 4.3 Hz), 
3.60 (t, 1H, J= 9.9 Hz), 1.87-1.74 (m, 2H), 1.62-1.16 (m, 28H), 0.89 (bt, 3H, J= 
6.7 Hz).13C-NMR (CDCl3): 53.0 (CH), 36.2 (CH2), 36.1 (CH2), 32.1 (CH2), 
29.9 (7xCH2), 29.7 (CH2), 29.6 (2xCH2), 29.0 (CH2), 26.9 (CH2), 22.9 (CH2), 
14.3 (CH3). 
General procedure for the preparation of 1,2-diazidoalkanes 
Compounds2a-2b (1.0 eq) and sodium azide (3.0 eq) were dissolved in 
dimethylformamide (1M) and the reaction was heated to 130 °C for 2 h. Ice was 
added to the mixture and the pH adjusted to ∼10 with NaOH. The mixture was 
extracted with diethyl ether (2×10 mL), and the extracts were concentrated with 
the help of a N2 flow. Due to the unstable nature of diazides, compounds 3a-3b 
were not isolated and characterized and were used as such for the following 
step. 
General procedure for the preparation of 1,2-diaminoalkanes 4a-4b 
Compounds 3a-3b (1.0 eq) were slowly added dropwise into a round-bottomed 
flask containing triphenylphosphine (2.2 eq) and THF/diethyl ether/conc. aq 
NH3(3:2:1, 0.3M) at room temperature. The reaction mixtures were the strirred 
at 60 °C for 3 h, then cooled, diluted with water and basified with NaOH. 
Extraction with diethyl ether followed by drying with Na2SO4, filtration and 
evaporation gave the crude diamines. Purification by silica-gel column 
chromatography (eluant toluene:2-propanol:ammonia 9:1:0.5) provided pure 
4a-4b as light yellow oils. 
1,2-Dodecanediamine (4a) 
Yield  56%, 1H-NMR (CDCl3): 2.69-2.53 (m, 2H), 2.36 (dd, 1H, J= 11.8, 7.8 
Hz), 1.68-1.52 (m, 6H), 1.38-1.09 (m, 20H), 0.79 (bt, 3H, J= 5.5 Hz).13C-NMR 




(5xCH2), 29.4 (CH2), 26.2 (CH2), 22.7 (CH2), 14.1 (CH3). ESI-MS(+): calcd for 
C14H32N2: 228.3; found: 229.3 (MH
+); 251.4 (MNa+). 
1,2-Octadecanediamine (4b): Yield 61%, 1H-NMR (CDCl3): 2.62 (dd, 1H, J= 
12.2, 3.7 Hz), 2.54 (m, 1H), 2.33 (dd, 1H, J= 12.1, 7.5 Hz), 1.33-1.08 (m, 34H), 
0.77 (bt, 3H, J= 6.3 Hz). 13C-NMR (CDCl3): 53.6 (CH),48.6 (CH2), 35.7 (CH2), 
31.9 (CH2), 29.7-29.5 (10xCH2), 29.3 (CH2), 26.2 (CH2), 22.6 (CH2), 14.1 
(CH3). ESI-MS(+): calcd for C18H40N2: 284.3; found: 285.5 (MH
+). 
General procedure for the preparation of compounds 5a-5b: Diamines 4a-
4b (1.0 eq) were dissolved in acetonitrile (1.5 M) at room temperature. 
Powdered K2CO3 (7.0 eq) and t-butyl 2-bromoacetate (4.5 eq) were added to the 
mixtures.The reaction mixture was stirred at 60 °C for 8 h.Inorganic salts were 
separated by filtration and the filtrate evaporated in vacuo. Crude compounds 
5a-5b were purified by gravimetric chromatography (eluant petroleum ether, 
ethyl acetate, 2-propanol9.4:0.4:0.2),  obtaining the pure tetraesters as clear 
light yellow viscous oils. 
Tetra-t-butyl 1,2-dodecanediamine-N,N,N’,N’-tetraacetate (5a): Yield 67%, 
1H-NMR (CDCl3): 3.49-3.34 (m, 8H), 2.85 (dd, 1H, J= 13.2, 6.1 Hz), 2.74 
(bquint, 1H, J= 6.1 Hz), 2.46 (dd, 1H, J= 13.2, 6.1 Hz), 1.42 (s, 18H), 1.41 (s, 
18H), 1.37 (m, 4H), 1.27-1.16 (m, 18H),0.84 (bt, 3H, J= 6.4 Hz). 13C-NMR 
(CDCl3): 171.7 (C), 170.9 (C), 80.7 (C), 80.4 (C), 61.1 (CH), 56.5 (CH2), 56.3 
(CH2), 53.3 (CH2), 32.0 (CH2), 30.9 (CH2), 30.0 (CH2), 29.7 (5xCH2), 29.4 
(CH2), 28.22 (CH3), 28.16 (CH3), 27.0 (CH2), 22.7 (CH2), 14.1 (CH3). ESI-
MS(+): calcd for C38H72N2O8: 684.5; found: 685.6 (MH
+), 707.6 (MNa+), 723.5 
(MK+),  629.5 (MH+-tBu). 
Tetra-t-butyl 1,2-octadecanediamine-N,N,N’,N’-tetraacetate (5b): 
Yield75%, 1H-NMR (CDCl3): 3.96 (d, 2H, J= 17.5 Hz), 3.85 (d, 2H, J= 17.5 
Hz), 3.82 (d, 2H, J= 17.2 Hz), 3.67 (d, 2H, J= 17.2 Hz), 3.46-3.33 (m, 2H), 3.05 




NMR (CDCl3): 171.4 (C), 170.6 (C), 80.5 (C), 80.1 (C), 60.9 (CH), 56.4 (CH2), 
56.2 (CH2), 53.2 (CH2), 31.9 (CH2), 30.7 (CH2),  29.8 (CH2), 29.6 (9xCH2), 
29.3 (CH2), 28.09 (CH3), 28.04 (CH3), 26.8 (CH2), 22.6 (CH2), 14.0 (CH3). 
ESI-MS(+): calcd for C42H80N2O8: 740.6; found: 741.6 (MH
+), 763.7 (MNa+), 
685.6(MH+-tBu), 707.5 (MNa+-tBu). 
General procedure for the preparation of the ligands DDTA and ODDTA 
Compounds 5a,b were treated with trifluoroacetic acid (10 mL) and heated to 
reflux for 30 min. After evaporated of volatiles, crude ligands DDTA and 
ODDTA were redissolved in methanol, precipitated with diethyl ether, isolated 
by centrifugation and washed with diethyl ether, then dried in vacuo obtaining 
the products as white solids.  
1,2-Dodecanediamine-N,N,N’,N’-tetraacetic acid (DDTA) 
1H-NMR (CD3OD): 3.93 (d, 2H, J = 17.5 Hz), 3.86 (d, 2H, J = 17.5 Hz), 3.80 
(d, 2H, J = 17.2 Hz), 3.64 (d, 2H, J = 17.2 Hz), 3.43-3.31 (m, 2H), 3.05 (bt, 
1H), 1.41-1.23 (m, 22H), 0.89 (bt, 3H, J ∼ 6.7 Hz). 13C-NMR (CD3OD): 170.7 
(C), 170.6 (C), 60.5 (CH), 54.5 (CH2), 54.2 (CH2), 52.3 (CH2), 31.7 (CH2), 
29.42 (3xCH2), 29.38 (2xCH2), 29.15 (2xCH2), 26.6 (CH2), 26.3 (CH2), 22.4 
(CH2), 13.1 (CH3). 
1,2-Octadecanediamine-N,N,N’,N’-tetraacetic acid (ODDTA) 
1H-NMR (CD3OD): 3.95 (d, 2H, J = 17.4 Hz), 3.85 (d, 2H, J = 17.4 Hz), 3.81 
(d, 2H, J = 16.8 Hz), 3.65 (d, 2H, J = 17.1 Hz), 3.45-3.28 (m, 2H), 3.04 (bt, 
1H), 1.43-1.15 (m, 30H), 0.89 (bt, 3H, 6.4 Hz). 13C-NMR (CD3OD): 172.5 (C), 
172.0 (C), 61.8 (CH), 55.8 (CH2), 55.3 (CH2), 53.6 (CH2), 33.1 (CH2), 30.79 
(CH2) × 7, 30.68 (CH2) × 2, 30.5 (CH2) × 2, 28.0 (CH2), 27.6 (CH2), 23.8 
(CH2), 14.4 (CH3). 
N,N,N’,N’-Tetrabenzyl-1,2-bis(benzotriazolyl)ethylenediamine (6) 
Dibenzylamine (10.01 g, 0.0507 mol) and 1H-benzotriazole (6.039 g, 0.0507 




was added to the reaction mixture at room temperature. After 8 h the mixture 
was filtered on a Buchner funnel and the solid washed with ethanol (2 × 30 mL) 
and dried, obtaining 13.84 g of a yellow oil (yield 84%), solidifying on standing 
to a off-white waxy solid. 
Synthesis of N,N,N’,N’-tetrabenzyl-13,14-hexacosanediamine (7) 
Mg turnings (2.070 g, 0.085 mol) and 1-bromododecane (19.94 g, 0.030 mol) 
were stirred in anhydrous tetrahydrofuran (15 mL) under nitrogen at room 
temperature. After 24 h compound 6 (12.013 g, 0.0369 mol) was added and the 
resulting grey solution stirred for 8h. The reaction mixture was filtered and 
evaporated in vacuo and the crude residue purified by gravimetric 
chromatography (eluant toluene), obtaining the diamine 7 as a light yellow solid 
(61% yield). Melting point 92.5-93.0°C. 1H-NMR (CDCl3): 7.39-7.19 (m, 
20H), 3.65-3.53 (m, 8H), 2.79 (bt, 2H), 1.74-1.46 (m, 4H), 1.44-1.16 (m, H), 
0.95 (bt, 6H, J = 6.7 Hz).13C-NMR (CDCl3): 140.8 (C), 128.9 (CH), 128.1 
(CH),126.7 (CH), 58.5 (CH), 54.7 (CH2), 32.1(CH2), 30.2 (CH2), 29.9 (4xCH2), 
29.6 (CH2), 28.2 (CH2), 27.1 (CH2), 22.9 (CH2), 14.3 (CH3). ESI-MS(+): calcd 
for C54H80N2: 756.6; found: 757.7 (MH
+). 
13,14-Hexacosanediamine (8) 
Ammonium formate (560.6 mg, 10.4 mmol) and Pd/C (500 mg) were dissolved 
in methanol (3 mL) and toluene (3 mL) under nitrogen. The tetrabenzylated 
diamine7 (761 mg, 1.0 mmol) was added and the reaction was heated at 
refluxed for 24 h. The mixture was filtered, evaporated and partitioned between 
water and dichloromethane (3 × 20 mL). The crude oily product was purified by 
gravimetric chromatography (eluant dichloromethane/methanol, 9.6:0.4→7:3) 
obtaining the pure diamine3c (82% yield).1H-NMR (CDCl3): 2.52 (bt, 2H), 
1.56 (bs, 4H), 1.41 (m, 4H), 1.33-1.18 (m, 40H), 0.86 (bt, 6H, J = 6.7 Hz). 13C-




29.5 (CH2), 26.7 (CH2), 22.8 (CH2), 14.2 (CH3).ESI-MS(+): calcd for 
C26H56N2: 396.4; found: 397.4 (MH
+). 
Tetra-t-butyl 13,14-hexacosanediamine-N,N,N’,N’-tetraacetate (9) 
Compound 8 (2.500 g, 0.0067 mol) was dissolved in acetonitrile (40 mL) and 
powdered K2CO3 (5 eq) was added. At room temperature t-butyl 2-
bromoacetate (4.2 eq) was slowly added dropwise. The reaction mixture was 
refluxed for 5 h, then filtered, evaporated in vacuo and the oily residue was 
purified by gravimetric chromatography (eluant 9.8:0.2 petroleum ether/ethyl 
acetate), obtaining  a clear colorless oil. (67% yield). 1H-NMR (CDCl3): 3.54 
(d, 4H, J= 16.9 Hz), 3.44 (d, 4H, J = 16.9 Hz), 2.57 (t, 2H, J = 6.0 Hz), 1.57-
1.48 (m, 4H), 1.42 (s, 36H), 1.32-1.19 (m, 36H), 0.86 (bt, 6H).13C-NMR 
(CDCl3): 172.0 (C), 80.5 (C), 65.0 (CH), 54.6 (CH2), 32.1 (CH2), 30.0 (CH2), 
29.9 (4xCH2), 29.5 (CH2), 28.8 (CH2), 28.3 (CH3), 28.1 (CH2), 22.8 (CH2), 15.8 
(CH3).ESI-MS(+): calcd for C50H96N2O8: 852.7; found: 853.8 (MH
+), 875.8 
(MNa+), 797.7 (MH+-tBu). 
13,14-Hexacosanediamine-N,N,N’,N’-tetraaceticacid (HCDTA) 
Compound 8 (3.500 g) was dissolved in trifluoroacetic acid (10 mL) and the 
reaction was stirred for 48 h. The solvent was evaporated and the oily residue 
was redissolved in methanol; slow addition of an excess of diethyl ether 
precipitated HCDTA as a white solid (1.80 g, 72% yield). Mp 186-188 °C 
(dec). 1H-NMR (CD3OD): 3.94 (d, 4H, J = 16.9 Hz), 3.75 (d, 4H, J = 18.1 Hz), 
3.34 (m, 2H), 1.58-1.46 (m, 4H), 1.38-1.25 (m, 40H), 0.89 (bt, 6H, J = 6.4 Hz). 
13C-NMR (CD3OD): 171.8 (C), 66.8 (CH), 54.0 (CH2), 33.0 (CH2), 30.8 (CH2), 
30.7 (4xCH2), 30.6 (CH2), 30.4 (CH2), 30.3 (CH2), 29.5 (CH2), 23.6 (CH2), 14.4 
(CH3). 
1
H NMR Relaxation Measurements 
The proton 1/T1 NMRD profiles were measured on a fast field-cycling Stelar 




0.00024 to 0.25 T (corresponding to 0.01-10 MHz proton Larmor frequencies). 
The relaxometer operates under computer control with an absolute uncertainty 
in 1/T1 of ± 1%. Additional data points in the range 15-70 MHz were obtained 
on a Bruker WP80 NMR electromagnet adapted to variable-field measurements 
Stelar Relaxometer. The exact concentrations of gadolinium were determined 
by measuring the bulk magnetic susceptibility shifts of the tBuOH 1H NMR 
signal on a Bruker Avance III spectrometer (11.7 T). The 1H relaxation times T1 
were acquired by the standard inversion recovery method with typical 90° pulse 
width of 3.5 µs, 16 experiments of 4 scans. The reproducibility of the T1 data 
was ±5%. The temperature was controlled with a Stelar VTC-91 (Stelar s.r.l., 
Mede, PV, Italy) air-flow heater equipped with a calibrated copper-constantan 
thermocouple (uncertainty of ±0.1°C). Variable-temperature 17O NMR 
measurements were recorded on a Bruker Avance III spectrometer (11.74 T, 
67.8 MHz for 17O) equipped with a 5 mm probe and standard temperature 
control units. Aqueous solutions of the complexes (14.5 mM) containing 1.0% 
of the 17O isotope (Cambridge Isotope) were used. The observed transverse 
relaxation rates were calculated from the signal width at half-height. 
Relaxivity was also measured with Bruker MQ20 Minispec spectrometer at 20 
MHz with the “inversion recovery” method (180° - τ - 90°) by using 8 different 
τ values. The temperature of  the sample holder was controlled with a 
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A unimolecular nanosized chelating agent (PEI-P) is prepared by 
functionalization of polyethyleneimine with phosphonic groups. The loading of 
PEI-P with Gd3+ ions leads to a paramagnetic nanosized system; relaxometric 





Paramagnetic systems are currently employed as MRI contrast agents (CAs), to 
increase the relaxation rate of the observed nuclei (mainly 1H) and allowing to 
acquire better diagnostic images in a shorter period (1).  
Different families of paramagnetic systems were developed in the last 30 years 




kinetic stability needed for a safe in vivo use (2). 
Small Gd3+ chelates dominate the clinical MRI CAs market, and are widely 
employed in a significant proportion of all MRI examinations; 
superparamagnetic iron oxide nanoparticles have been used as “negative” CAs 
(3). 
The low sensitivity of MRI compared to other imaging techniques drove an 
intensive search for high relaxivity MRI CAs (relaxivity is defined as the 
increase of the relaxation rate of 1H nuclei of a 1 mM solution of the CA). 
Improvements in the family of Gd3+ chelates was accomplished mainly through: 
i) raising in the number (“q”) of coordinated water molecules (fighting to 
maintain a suitable complex stability) (4); ii) increasing the number of 
paramagnetic metal ions, e.g. by using polynuclear complexes; iii) slowing the 
rotational tumbling rate of the paramagnetic chelate (5), by inclusion (6), 
interaction (7) or link with a macromolecular system such as proteins, polymers 
(8), dendrimers (9) and nanoparticles (10). 
The latter strategy usually relies on the preliminary preparation of Gd3+-chelate 
incorporating a free functional group, subsequently used for conjugation to the 
selected macromolecule. The drawback of this approach is the need for a 
bifunctional chelating agent (BFCA) (11) and the possibility that a flexible 
linkage between the metal complex and the macromolecule can leave the 
paramagnetic chelate free to rotate, vanifying the devised reduction of its 
rotational rate. 
We envisage that the use of the backbone atoms of a polymeric macromolecule 
to coordinate metal ions can lead to significant improvements of this strategy: i) 
avoiding expensive BFCAs or their lenghty preparations, ii) tightly embracing 
the paramagnetic metal ions in the slowly moving macromolecule; iii) 
exploiting the polymeric nature of the macromolecule to bind several metal ions 




In this manuscript we describe the preparation of a polymeric chelating agent 
and the corresponding Gd3+ complex (PEI-P, Scheme 1), and the evaluation of 



































































































































































Scheme 1: Preparation of PEI-P-Gd3+ (idealized average structure of the 





Commercially available low MW polyethyleneimine (PEI) was chosen as 
preferred scaffold to build the polymeric chelating agent for several different 
reasons: i) amino groups in the polymer backbone may play both a structural 
and a coordinating role; ii) primary and secondary amino groups may be easily 
functionalized with coordinating groups, targeting moieties or tailoring 
residues; iii) the ethylene spacer between two nitrogen atoms allows metal 
chelation through the formation of stable five-membered rings; iv) PEI is a 
freely water soluble and cheap starting material. Phosponate coordinating 
groups were introduced by an adaptation of the classical Moedritzer-Irani 
protocol (12). 
Previous example of functionalized PEI as a coordinating polymer may be 
found in the removal of toxic metal ions (13), while a phosphonated high 
molecular weight derivative was employed to bind 99mTc and 153Sm as potential 
therapeutic radiopharmaceuticals (14). In the field of MRI CAs, a PEI grafted 
with macrocyclic chelating agents was reported (15), but in this system the 
polymer do not actively participate in the coordination of the metal ion but 




General: Reagents and dialysis tubes were obtained from Aldrich and used 
without further purification. All water solutions were prepared from ultrapure 
laboratory grade water (18 MΩ·cm) obtained from Millipore/MilliQ 
purification system. 
Preparation of functionalized polyethyleneimine (PEI-P) 
Polyethyleneimine (MW 1800-2000, 50% aq solution, 10.00 g) was dissolved 




g) was added in one portion and the resulting mixture was brought to reflux. 
Paraformaldehyde (7.51 g) was added portionwise during 1 h, then the mixture 
was refluxed for 8 h and left overnight at room temperature. Concentration in 
vacuo to approx half volume, followed by slow addition of excess ethanol 
induced precipitation of a off-white gummy product, isolated by decantation 
and washed with ethanol. The crude product was redissolved in the minimum 
volume of conc. HCl/H2O 1:1 and reprecipitated by slow addition of an excess 
ethanol, followed by decantation and repeated washing with ethanol. 
Exhaustive elimination of low molecular weight reagents and byproducts was 
accomplished through extensive dialysis against water (benzoylated dialysis 
tubes, MW cut-off 2000, 5 cycles). The retentate was evaporated to dryness 
giving PEI-P (13.97 g). 1H-NMR (D2O, 300 MHz, 333K): 4.05-2.95 (br s). 
13C-
NMR (D2O, 75.4 MHz, 333K): 56.0-52.5 (br, CH2), 56.0-48.7 (br, CH2), 46.3-
44.8 (br, CH2). 
31P-NMR (D2O, 121.4 MHz, 333K): 20.1-7.2 (br s). 
Preparation of the Gd-PEI-P complex 
PEI-P (1.569 g) was dissolved in water (15 mL) and gadolinium hydroxide 
(freshly precipitated with NaOH 1M from an aqueous solution containing 1.997 
g GdCl3, centrifuged and washed with distilled water). The suspension was 
stirred at room temperature overnight and for additional 2 h at 60°C and then 
filtered. The filtrate was dialyzed (benzoylated dialysis tubes, MW cut-off 
2000) against: i) water (1 cycle); ii) EDTA disodium (25 mM, pH 7) (5 cycles), 
to remove loosely bound Gd3+ ions; iii) water (3 cycles). The retentate was 
lyophilized to give Gd-PEI-P (1.763 g) as a white powder. 
Relaxometric Characterization  
The longitudinal water proton relaxation rate as a function of the pH was 
measured by using a Stelar Spinmaster (Stelar, Mede, Pavia, Italy) spectrometer 
operating at 20 MHz, by means of the standard inversion−recovery technique. 




with a copper-constantan thermocouple (uncertainty 0.1 °C). The proton 1/T1 
NMRD profiles were measured over a continuum of magnetic field strength 
from 0.00024 to 0.47 T (corresponding to 0.01−20 MHz proton Larmor 
frequencies) on a Stelar field-cycling relaxometer. The relaxometer works 
under complete computer control with an absolute uncertainty in 1/T1 of 1%. 
Data points from 0.47 T (20 MHz) to 1.7 T (70 MHz) were collected on a Stelar 
Spinmaster spectrometer working at variable field. The concentration of the 
gadolinium complex solutions, for relaxometric characterization, was 
determined by mineralizing a given quantity of the sample solution by the 
addition of 37% HCl at 120°C overnight. From measurement of the observed 
relaxation rate (R1obs) of the acidic solution and knowing the relaxivity (r1p) of 
Gd3+ aquaion in acidic conditions (13.5 mM-1s-1), it was possible to calculate 
the exact gadolinium(III) concentration (this method was calibrated using 
standard ICP solutions, and the accuracy was determined to be <1%). 
 
Results and discussion 
 
Relaxometric properties 
Relxometric investigations on Gd-PEI-P were performed on 1 mM solutions 
prepared in isotonic phosphate buffered saline (PBS). Solutions of Gd-PEI-P  
in water showed aggregation phenomena leading to partial precipitation of the 
polymer and suggesting a stabilizing role of counterions with respect to the 
polymer charges. Absence of free Gd3+ ions was checked by UV-Vis 
spectrophotometric analysis with Xylenol Orange (16). 
The relaxivity value was determined to be 10.7 mM-1s-1 in PBS (pH 7.0, 25°C, 
20 MHz)  and linear in the range of concentration 0-5 mM. A higher value of 




attributed to the formation of high molecular weight aggregates with a reduced 
rotational rate and finally leading to the above cited precipitation. Assuming the 
idealized structure of Scheme 1 for the polymeric chelate, containing an 
extimated number of 7-9 Gd3+ ions, an attractive overall relaxivity of 75-96 
mM-1s-1 could be calculated for each nanosized unimolecular system, one order 
of magnitude higher than the values showed by clinically employed Gd3+-





Figure 1: A) Relaxivity vs pH for Gd-PEI-P, 21.5 MHz. B) NMRD profiles 
registered for Gd-PEI-P at neutral and basic pH. 
 
The relaxivity of Gd-PEI-P was studied as a function of pH (Fig. 1A), 
revealing an unusual behaviour. The paramagnetic system shows an asymmetric 
bell-shaped trend, with the relaxivity peaking around pH 7. The decrease in the 
relaxivity observed at acidic pH is related to the partial precipitation, likely 
induced by protonation-driven formation of larger aggregates; on the other side, 
basic pH values lead to a monotonic reduction of relaxivity, attributed to the 
displacement of coordinated water molecules by anions such as hydroxide, 




The composite behaviour of the relaxivity of Gd-PEI-P on varying the pH 
prompted us to explore in detail the mechanisms involved. NMRD profiles of 
Gd-PEI-P at neutral and acidic pH were registered and are reported in Fig. 1B; 
both NMRD profiles show a peak of relaxivity centered around 50 MHz, 
typically observed in slowly rotating systems.  
The 17O NMR R2 values of Gd-PEI-P were determined at 14.1 T in the 
temperature range 5-70°C (Fig. 2B). The experimental data show a nearly 
exponential increase with decreasing temperature, indicating the occurrence of 
a fast exchange regime for the coordinated water molecule(s), even if the 
comparison with Gd-DO3A and Gd-DOTA where the coordinated water 
molecules are respectively 2 and 1, clearly shows a lower level of hydration in 





Figure 2: A) 17O NMR R2 of Gd-PEI-P compared to Gd-DO3A and Gd-DOTA. 
B) 
17
O NMR R2 of Gd-PEI-P at neutral and basic pH. 
 
The 17O NMR spectroscopic data were analyzed in terms of the Swift-Connick 
equations (17), whereas the NMRD profiles were fitted to the standard 




The results of the fitting procedure are summarized in Table 1. 
 
Table 1 Parameters obtained from the fitting of NMRD profiles and 17O NMR 


































a Obtained from 17O NMR data. 
 
The fast exchange regime of the coordinated water molecules is demonstrated 
by their exchange lifetime, located under 100 ns from 17O NMR data. The 
significantly high value of τR, close to 2 ns, can be easily ascribed to the 
nanometric size of the system, clearly fulfilling the task to include multiple 
paramagnetic metal centers in a slowly rotating context.  
The favorable combination of these parameters explains the >10 mM-1s-1 values 
of observed relaxivities at the bell apex, that associated with the presence of 
multiple Gd3+ ion in the molecular system lead to a nanosized CA with 
attractive performances, especially in the 50-60 MHz region where a large 
portion of the clinical MRI scanner operate. 
Stability evaluation 
Stability issues ensuing from the observation of diseases related to chelate 
dissociation (18) require a mandatory evaluation of  the stability of Gd3+-
complexes. Even if kinetic factors may strongly influence the behaviour of the 




needed to avoid the release of the Gd3+ ion under physiological conditions. 
Relaxometric data indicates that the metal centers coordinates only 0-1 
molecules of waters: it is reasonable to expect that the lanthanide metal ions, 
usually accomodating 8-9 donor groups in their inner sphere, are coordinated in 
this system by a number of functional groups ranging from 7 to 9. Either amino 
groups of the PEI backbone or phosphonic groups may contribute to the 
coordination, provided that they are suitably placed, either by connectivity or by 
spatial proximity. The strong participation of the polymeric ligand to the 
coordination of the metal ions may be likely ascribed to the preliminary 
selection operated by elimination of loosely bound Gd3+ ions by extensive 
dialysis against EDTA (hence “loosely bound” is to be intended as “bound with 
a formation constant lower than Gd-EDTA”). 
The heterogeneous nature of the polymeric system studied in this work implies 
that the metal ions included in the polychelating matrix experience different 
coordinating environments, determined by the several possible combination of 
amino and phosphonic groups. This precludes the determination of accurate 
formation constants for the single coordinating arrangements. Nevertheless, an 
extimation of an average formation constant could be useful to assess the 
overall stability of the system as a whole. 
To this purpose, competition experiments were performed, tackling Gd-PEI-P 
with ligands as EDTA and DTPA, for which the formation constant of the 
corresponding Gd-complexes are known. The relaxivity of a 1 mM solution of 
Gd-PEI-P was measured after the addition of increasing amounts of EDTA or 




























Figure 3: Relaxometric titration of Gd-PEI-P with EDTA and DTPA (20 MHz, 
298K.) 
 
Fitting the results with the literature values of KGd-EDTA and KGd-DOTA allowed to 
obtain an average value of the formation constant Log KGd-PEI-P = 21.6, 
noticeably higher than the safety limit previously stated. 
Interaction with meglumine 
The unusual behaviour registered for Gd-PEI-P on varying the pH led us to 
explore the possibility to modify the solution properties of the unimolecular 
nanosized CAs. The idealized structure of Gd-PEI-P depicted in Scheme 1 
shows that the outer surface contains a large number of phosphonic groups, 
some of them involved in the metal complexation and some other free. The 
ionization of these groups leads to an overall negative charge of the surface: 




mV, indicating that the phosphonates negative charge largely overcomes the 
positive charges of the protonated amines of the PEI backbone. 
We decided then to use meglumine (N-methylglucamine) as a cationic surface 
modifier. The use of this biocompatible and highly hydrophilic amine was 
already described to increase the relaxometric properties of a negatively 
charged CA, in virtue of the formation of an ion pair, leading to a large increase 
of the second sphere hydration of the metal complex (19). In our intention, 
meglumine could be beneficial for Gd-PEI-P: i) exerting a protective effect 
against aggregation; ii) improving the solubility profile of the nanosized 
system; iii) enhancing the relaxivity of the exposed metal ions through the 
hydration boosting mechanism reported previously. 
Relaxometric titration of a Gd-PEI-P solution with meglumine (Fig. 4) shows 
the expected improvement of relaxivity, growing from 10.7 mM-1s-1 towards a 



































Figure 4: Relaxometric titration of Gd-PEI-P with meglumine (20 MHz, 298K). 
 
The shielding effect of the meglumine coating becomes apparent with the 
determination of the relaxivity as a function of pH for the supramolecular 
adduct (Fig. 5), where the relaxivity fall observed at basic pH values of the 
asymmetric bell-shaped behaviour of pristine Gd-PEI-P is completely 
removed, with relaxivity being approximately unchanged in the pH range 8-
12.5. 
A less pronounced effect is observed even at acidic pH values, where the 
relaxivity decrease is shifted leftwards of ∼ 1 pH unit, further widening the 
stability window of the system. 
Meglumine plays then a double shielding role, either against the coordinating 
anions adversely affecting the relaxivity at basic pH, or preventing the 



























Figure 5: Relaxivity vs pH for meglumine-coated Gd-PEI-P ([Gd-PEI-P]=70 
µM, [meglumine]=100mM, 20 MHz, 298K).  
 
A third shielding effect was finally observed when tackling the thermodynamic 
stability of meglumine-coated Gd-PEI-P with DTPA in the same conditions 
employed for the relaxometric titration reported in Fig. 3. It was indeed 
observed (Fig. 6) that higher concentration of DTPA (roughly threefold) are 
needed to remove the metal ions from meglumine-coated Gd-PEI-P compared 
to native Gd-PEI-P, paving the way to an increase in the safety profile of this 
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Figure 6: Comparison of the relaxometric titration of meglumine-coated and 




In conclusion we reported the preparation of an original unimolecular nanosized 
Gd-based contrast agent for MRI (Gd-PEI-P), based on polyethyleneimine 
functionalized with phosphonate groups. Relaxometric investigation 
highlighted an unusual behaviour of this paramagnetic system, with a 
remarkable relaxivity, the latter varying with an asymmetric bell-shaped profile 
as a function of pH. The high relaxivity value was attributed through NMRD 
and 17O NMR measurements to a favourable combination of a fast exchange of 




to the system by its unimolecular nanosized structure. Competition experiments 
with known ligand showed a noteworthy thermodynamic stability of the 
polychelate. 
Significant improvements of the relaxometric properties and the stability 
profiles of Gd-PEI-P was obtained by interaction with meglumine, acting as a 
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Citotoxicity in the µM range was observed in cancer cell lines treated with 
N,N,N’,N’-tetrabenzyl-4,5-diamino-2-cyclopentenone. Cell cycle analysis on 
HeLa cells showed a clear G1 phase arrest. A preliminary SAR on structural 




Cancer is currently one of the most relevant causes of death (1, 2). 
Identification of new compounds to be used in oncological therapy is nowadays 
one of the greatest challenges for medicinal chemists. Improvement of known 
active compounds is an immediate strategy to find new drugs to be tested in 
clinical trials. Screening of known compounds for unknown bioactivities is an 




easier by the usually larger availability of the chemicals and of the information 
about their chemical properties, synthesis and reactivity. 
The majority of all drugs contains amine groups, hence we focused our 
attention on synthetic amines, and particularly on 1,2-diamines. The 1,2-
diamino moiety can be found in many natural and synthetic substances showing 
valuable biological properties (3, 4). Among them is possible to cite, for 
instance, antidepressant agents (5), antiarrhythmics (6), antimicrobial (7),  
antiparasitic against Leishmania spp and Trypanosoma cruzi (8, 9) and 
anticancer drugs. Antitumoral properties of cisplatin (10) and its success in 
chemotherapy brought about the synthesis of many diamino-platinum 
complexes with improved properties, as oxaliplatin and DWA 2114R. Several 
1,2-diamino-platinum complexes were prepared and tested for antitumoral 
activity, making these compounds the most popular examples of 1,2-diamino 
moiety in medicinal chemistry (11-17). Few others “non-metallic” compounds 
possessing the 1,2-diamine moiety showed anticancer activity, too. Bis-
naphthalimides linked by an ethylenediamine moiety, like DMP 840, showed an 
excellent activity against several human tumor xenografts in mice (18, 19). 
Balanol, a natural compound extracted from the fungus Verticillum balanoides, 
was found to be a potent inhibitor of PKC (protein kinase C), the latter playing 
a key role in cell growth, metabolism and differentiation (20).  
During our search of synthetic approach to vicinal diamines we were 
intrigued by the recent interest on a RORC (Ring-Opening/Ring-Closure) 
reaction between furfural and secondary amines (21-25). Stenhouse explored 
this reaction with aromatic amines in presence of acidic catalysts more than 150 
years ago, in order to obtain compounds with dye properties (26-29). Noticing 
that no biological studies of this interesting structure have been yet undertaken, 
we decided to investigate the cytotoxicity of the diamines obtained by the acid 






Compound IC50 (µM) 
1 3.3 ± 1.0 
2 12.0 ± 4.7 
3 4.3 ± 0.9 
4 41.7 ± 0.7 
5 > 100 
6 > 100 
7 > 100 
8 11.1 ± 2.2 
9 10.8 ± 1.9 
10 69.1 ± 4.7 
 
Table 1: Citotoxicity determination of the compounds after 48h expeosure to 
HeLa cell line, IC50 values are reported. 
 
This series of preliminary tests revealed that N,N,N’,N’-tetrabenzyl-4,5-
















Figure 1: Cell cycle analysis after 16 hours treatment of HeLa cells with 1 at 10 
µM. Pie-charts for the percentages of the different cell phases for control and 




































Figure 3: Histogram representation of cell phases ratios for control and after 
treatment with 1, 2, 3, 8, 9, 10, cisplatin and combrestatine at the reported 
concentrations. 
 
It is interesting to note that compound 1 satisfies all but one Lipinski’s Rules 
(30): there are less than 5 H-bond donors, the molecular weight is less than 500 
(MW = 472.6) and there are less than 10 H-bond acceptors (two nitrogen atoms 
and one ketone). The logP of 1 is the only exception, being higher than 5 (logP 
= 7.05) as a result of the presence of four aromatic rings; nevertheless one 
violation of those rules is usually accepted (31). Compound 1 applies as a 































Scheme 1: Synthesis of N,N,N’,N’-tetrabenzyl-4,5-diaminocyclopentenone (1) 




















R=CH3 (3), C6H5 (4), 
4-NO2-C6H4 (5), 4-F-C6H4 (6),
n-C13H27 (7)  
 




















































Scheme 3: Synthesis of tetrabenzylic-, tribenzylic- and N,N’-dibenzylic-
derivatives (8-10). 
 
Results and Discussion 
 
Compound 1 was synthesized in racemic form in good yields from the 
condensation of furfural with dibenzylamine in ethanol; the reaction was 
catalyzed by BF3 and run in the presence of 4 Å molecular sieves. Cytotoxicity 
in HeLa cancer cell line was used as first screening for the bioactivity of this 
molecule. Dose/response curves were performed exposing cells for 48 hours to 
concentration of 1 ranging from 10 nM to 100 µM. Gratifyingly the IC50 of 
compound 1 was localized in the micromolar range (3.3 ± 1.0 µM). To further 
investigate the effect of this molecule we performed a cell cycle analysis after 
16 hours of exposure to the drug at different concentrations above the IC50 
value. Compound 1 showed a clear G1 phase arrest at the concentration of 
10µM, clearly recognizable in figure 1. Several antitumoral drugs act blocking 
cells in G1 phase ultimately leading to cell death, although this can be 
accomplished by different mechanisms. For example etoposide (32) and 
irinotecan (33) stop the synthesis of DNA by the inhibition of Topoisomerase. 




examples for this action are alvocidib (34), P276-00 (35), SNS-032 (36), and 
roscovitine (37). 
The bioactivity of 1 prompted us to carry out a preliminary SAR by preparing 
selected derivatives (Scheme 1) and screening their cytotoxicity. Reduction of 
the conjugated ketone with NaBH4 in ethanol afforded the cyclopentanol ring of 
2 with complete diastereoselectivity (cis,trans- isomer obtained) due to the 
directing influence of the steric hindrance of the 5-dibenzylamino substituent. 
O-Acetylation and O-benzoylation with the corresponding anhydrides in basic 
condition afforded derivatives 3-4; 4-nitrobenzoyl-, 4-fluorobenzoyl- and 
hexadecanoyl-esters were obtained by reaction with the corresponding acyl 
chloride (compounds 5-7) in the presence of a suitable base. 
As with compound 1, cytotoxicity in HeLa cancer cell line was used to 
preliminarily evaluate the bioactivity of the derivatives. Dose/response curves 
were performed for all compounds on cells treated for 48 h to concentration 
ranging from 10 nM to 100 µM (figure 2). The resulting IC50 values are 
reported in table 1, showing a hierarchical potency of the compounds as 
1~3>2>4>5~6~7. Cell cycle analysis for compounds 2-3 was performed by 16 
hours exposure at different concentrations above the IC50 specific values for 
each compound. Only compound 3 showed a clear G1/S transition block at the 
concentration of 10 µM similar to that observed for compound 1 (figure 3). The 
percentage of cells in G1 increases about 20% and cells in S phase decrease 
from 30% to 10%. Compound 2 showed only a weak effect on cell phases ratio 
at 100 µM, indicating a low efficiency on the cell phase regulation. Compounds 
5-7 were not examined due to their critically high IC50 values. The H-bond 
acceptor ability of the oxygen atom of compound 1 appears to be important for 
the activity. Either the reduction of the α,β-unsaturated ketone or the increased 
steric hindrance, resulting by the acylation of the hydroxyl group to both 




reported in Table 1. Only the acetylation of the hydroxylic function raised the 
activity of compound 2 to a level comparable to 1. The Michael acceptor ability 
of the α,β-unsaturated ketone of the cyclopentenone ring, known to determine a 
cytotoxic inhibition of the G1-CDK activity for prostaglandines PGA1 and 
PGA2 (38, 39), does not appear to play a key role in the activity of these 
compounds. 
Additional work was dedicated to verify if the four benzyl groups present in 1 
are involved in the bioactivity. To this purpose, we selected the commercial 
available trans-1,2-cyclohexanediamine to mimic the cyclic backbone of 1 and 
implanted on the nitrogen atoms a variable number of benzyl groups (n = 2-4) 
through a standard alkylation procedure; chromatographic separation of the 
reaction mixture yielded compounds 8-10 (Scheme 1). 
Cytotoxicity in HeLa cancer cell line for these molecule was evaluated with the 
same protocol used for compounds 1-7, affording the IC50 values for 
compounds 8-10, reported in table 1. The diamine 8, bearing four benzyl groups 
on the two nitrogen atoms of the trans-cyclohexanediamine, is structurally the 
most similar to compounds of the series 1-7. Size and conformational 
differences between the alicyclic rings were not considered at this preliminary 
level of screening. The IC50 value for this compound is close to that observed 
for compound 2, with the lack of the H-bond acceptor group on the cyclohexane 
ring as a possible reason of the low cytotoxicity. Cytotoxicity is maintained 
leaving three benzylic substituents, the IC50 value of compound 9 being 
practically the same to that observed for compound 8. The cytotoxicity 
dramatically drops when another benzyl group is removed, clearly showing an 
active role of three benzyl moieties in the mechanism underlying the biological 
activity. 
Cell cycle analysis of these compounds showed no visible effect of 8 on cell 




at 20 µM was noted for 9, while the G1 phase arrest decreases dramatically 
when the molecule bears only two benzyl groups, showing just a weak effect at 
140 µM for compound 10. If the removal of one benzyl has practically no effect 
on the IC50 value, the block of the G1/S transition seems to be influenced, likely 





Interesting bioactivities were observed in N-benzylated alicyclic 1,2-diamines. 
The most actives compounds, 1 and 3, showed IC50 values of 3.3 and 4.3 µM 
respectively on HeLa cancer cells. Analysis of the cell cycle showed selective 
blocking of the G1/S transition (G1 phase arrest). Preliminary SAR studies 
evidenced the importance of a H-bond acceptor close to the amine groups and at 
least 3 benzyl groups on the nitrogen atoms to retain the reported activity. A 
pharmacological study will be undertaken in order to identify the biological 
target(s) linked to the G1/S transition block underlying the cytotoxicity of these 
compounds. A wider SAR will be useful to explore in detail this class of 









N,N,N’,N’-Tetrabenzyl- 4,5-diamino-2-cyclopenten-1-one (1) 
Furfural (20.0 g, 208 mmol) and dibenzylamine (82.1 g, 416 mmol) were 
dissolved in ethanol (150 mL). Boron trifluoride etherate (14.8 g, 104 mmol) 
and 4Å molecular sieves were added and the resulting reaction mixture was 
stirred at room temperature for 2 days. The reaction mixture is then heated to 
reflux and filtered hot. On cooling the filtrate released a voluminous precipitate, 
isolated by centrifugation and washed with cold ethanol. The product was dried 
in vacuum, affording N,N,N’,N’-tetrabenzyl- 4,5-diamino-2-cyclopenten-1-one 
1 (81.6 g, 83%) as a yellowish powder. 1H-NMR (CDCl3, 300MHz, 298K) δ: 
7.58 (dd, 1H, J=6.1, 2.1Hz), 7.36-7.19 (m, 20H), 6.20 (dd, 1H, J=6.1, 1.8Hz), 
4.06 (dt, 1H, Jd=2.8Hz, Jt=2.1Hz), 3.83 (d, 2H, J=13.2Hz), 3.62 (d, 1H, 
J=3.1Hz), 3.55 (d, 2H, J=13.2Hz), 3.39 (s, 4H). 13C-NMR (CDCl3, 75.4MHz, 
298K) δ: 206.1 (C), 163.1 (CH), 139.4 (C), 135.6 (CH), 129.6 (CH), 128.7 
(CH), 128.35 (CH), 128.29 (CH), 127.24 (CH), 127.17 (CH), 64.5 (CH), 63.4 
(CH), 55.1 (CH2), 54.7 (CH2). Mp=106-107 °C. 
 
N,N,N’,N’-Tetrabenzyl-2,3-diaminocyclopentan-1-ol (2) 
N,N,N’,N’-tetrabenzyl-4,5-diamino-2-cyclopenten-1-one 1 (20.0 g, 42.4 mmol) 
was dissolved in 2-propanol (250 mL) and sodium borohydride (6.4 g, 169.6 
mmol) was added at room temperature. The resulting reaction mixture was 
stirred at room temperature for 3 hours, checking periodically by TLC 
(CH2Cl2/MeOH 9/1). The solution was cooled to 0°C with an ice bath and 200 
mL of 2M HCl solution was slowly added with vigorous stirring. After 30 
minutes, sodium carbonate was added in small portions to bring to pH 10 and 




organic extracts were combined and dried over sodium sulfate. The drying 
agent was filtered and washed with dichloromethane. The solvent was removed 
by evaporation under reduced pressure, affording N,N,N’,N’-tetrabenzyl-2,3-
diaminocyclopentan-1-ol (19.8 g, 98%) as a white solid. 1H-NMR (CDCl3, 
300MHz, 298K) δ: 7.41-7.16 (m, 20H), 3.98 (q, 1H, J=4.8Hz), 3.89 (d, 2H, 
J=14.4Hz), 3.82 (d, 2H, J=13.5Hz), 3.74-3.62 (m, 1H), 3.61 (d, 2H, J=14.1Hz), 
3.36 (d, 2H, J=13.5Hz), 3.28 (dd, 1H, J=8.4, 6.0Hz), 2.07-1.81 (m, 2H), 1.80-
1.64 (m, 2H). 13C-NMR (CDCl3, 75.4MHz, 298K) δ: 139.56 (C), 139.46 (C), 
129.3 (CH), 128.9 (CH), 128.4 (CH), 127.2 (CH), 127.0 (CH), 70.8 (CH), 65.4 
(CH), 60.7 (CH), 55.8 (CH2), 55.0 (CH2), 31.5 (CH2), 19.0 (CH2). 
 
N,N,N’,N’-tetrabenzyl-2,3-diaminocyclopent-1-yl acetate (3) 
N,N,N’,N’-Tetrabenzyl-2,3-diaminocyclo-pentan-1-ol 2 (250 mg, 0.525 
mmol) was dissolved in dichloromethane (5 mL). Acetic anhydride (100 µL, 
107 mg, 1.05 mmol) and 4-dimethylaminopyridine (13 mg, 0.10 mmol) were 
added at room temperature and the resulting reaction mixture was stirred 
overnight. The solution was washed thrice with a saturated solution of sodium 
carbonate and twice with a saturated solution of sodium chloride. The organic 
phase was then dried over sodium sulfate, filtered and the solvent was removed 
by evaporation under reduced pressure. The crude product was purified by 
gravimetric chromatography on silica gel column (petroleum ether/ethyl acetate 
95:5 as eluant) giving 250 mg of N,N,N’,N’-tetrabenzyl-2,3-diaminocyclopent-
1-yl acetate (248 mg, 0.49 mmol, 93%) as a white amorphous solid. 1H-NMR 
(CDCl3, 300MHz, 298K) δ: 7.54-7.24 (m, 20H), 5.42 (td, 1H, Jt=5.3Hz, 
Jd=2.2Hz), 3.96 (d, 2H, J=14.4Hz), 3.91-3.79 (m, 1H), 3.87 (d, 2H, J=13.8Hz), 
3.74 (d, 2H, J=14.4Hz), 3.42 (d, 2H, J=13.5Hz), 3.35 (dd, 1H, J=10.4, 5.5Hz), 
2.03 (s, 3H), 1.99-1.83 (m, 2H), 1.73-1.58 (m, 2H). 13C-NMR (CDCl3, 




128.4 (CH), 127.1 (CH), 126.9 (CH), 75.3 (CH), 61.8 (CH), 58.7 (CH), 55.6 
(CH2), 54.4 (CH2), 28.8 (CH2), 21.8 (CH3), 18.7 (CH2). 
 
N,N,N’,N’-tetrabenzyl-2,3-diaminocyclopent-1-yl Benzoate (4)  
N,N,N’,N’-Tetrabenzyl-2,3-diaminocyclo-pentan-1-ol 2 (250 mg, 0.525 mmol) 
was dissolved in dichloromethane (5 mL). Benzoic anhydride (240 mg, 1.05 
mmol) and 4-dimethylaminopyridine (13 mg, 0.1 mmol) were added at room 
temperature and the resulting reaction mixture was stirred overnight. The 
solution was washed thrice with a saturated solution of sodium carbonate and 
twice with a saturated solution of sodium chloride. The organic phase was then 
dried over sodium sulfate, filtered and the solvent was removed by evaporation 
under reduced pressure. The crude product was purified by gravimetric 
chromatography on silica gel column (petroleum ether/ethyl acetate 95:5 as 
eluant) affording N,N,N’,N’-tetrabenzyl-2,3-diaminocyclopent-1-yl benzoate 
(170 mg, 56%) as a white solid. 1H-NMR (CDCl3, 300MHz, 298K) δ: 7.94 (d, 
2H, J=8.3Hz), 7.63-7.19 (m, 23H), 5.68 (bs, 1H), 3.99 (d, 2H, J=13.8Hz), 3.98-
3.82 (m, 1H), 3.88 (d, 2H, J=13.4Hz), 3.67 (d, 2H, J=14.1Hz), 3.42 (d, 2H, 
J=13.5Hz), 3.43-3.34 (m, 1H), 2.05-1.86 (m, 2H), 1.84-1.63 (m, 2H). 13C-NMR 
(CDCl3, 75.4MHz, 298K) δ: 166.1 (C), 140.5 (C), 140.0 (C), 133.0 (CH), 130.8 
(C), 129.8 (CH), 129.2 (CH), 128.6 (CH), 128.5 (CH), 128.33 (CH), 128.28 
(CH), 127.0 (CH), 126.9 (CH), 74.9 (CH), 62.0 (CH), 58.2 (CH), 55.3 (CH2), 
54.4 (CH2), 28.5 (CH2), 18.1 (CH2). 
 
N,N,N’,N’-Tetrabenzyl-2,3-diaminocyclopent-1-yl 4-Nitrobenzoate (5) 
N,N,N’,N’-Tetrabenzyl-2,3-diaminocyclopentan-1-ol 2 (250 mg, 0.525 mmol) 
was dissolved in dichloromethane (5 mL). 4-Nitrobenzoyl chloride (195 mg, 
1.05 mmol), triethylamine (290 µL, 160 mg, 2.1 mmol) and 13 mg of 4-




the resulting reaction mixture was stirred for 3 hours, checking periodically by 
TLC. The solution was washed thrice with a saturated solution of sodium 
carbonate and twice with a saturated solution of sodium chloride. The organic 
phase was then dried over sodium sulfate, filtered and the solvent was removed 
by evaporation under reduced pressure. The crude product was purified by 
gravimetric chromatography on silica gel column (petroleum ether/ethyl acetate 
95:5 as eluant) giving N,N,N’,N’-tetrabenzyl-2,3-diaminocyclopent-1-yl 4-
nitrobenzoate (290 mg, 0.46 mmol, 88%) as a white solid. 1H-NMR (CDCl3, 
300MHz, 298K) δ: 8.20 (d, 2H, J=8.6Hz), 7.97 (d, 2H, J=8.6Hz), 7.55-7.14 (m, 
20H), 5.62 (bs, 1H), 3.92 (d, 2H, J=14.7Hz), 3.88 (d, 2H, J=14.1Hz), 3.97-3.81 
(m, 1H), 3.61 (d, 2H, J=14.1Hz), 3.45-3.32 (m, 1H), 3.38 (d, 2H, J=13.2Hz), 
2.09-1.83 (m, 2H), 1.81-1.63 (m, 2H). 13C-NMR (CDCl3, 75.4MHz, 298K) δ: 
164.2 (C), 150.5 (C), 140.2 (C), 139.7 (C), 136.0 (C), 130.7 (CH), 129.2 (CH), 
128.3 (CH), 127.1 (CH), 126.9 (CH), 123.6 (CH), 76.4 (CH), 62.0 (CH), 58.1 
(CH), 55.5 (CH2), 54.4 (CH2), 28.3 (CH2), 17.7 (CH2). 
 
N,N,N’,N’-Tetrabenzyl-2,3-diaminocyclopent-1-yl 4-Fluorobenzoate (6) 
N,N,N’,N’-Tetrabenzyl-2,3-diaminocyclopentan-1-ol 2 (250 mg, 0.525 mmol) 
was dissolved in dichloromethane (5 mL). 4-Fluorobenzoyl chloride (165 mg, 
1.05 mmol), triethylamine (290 µL, 160 mg, 2.1 mmol) and 4-
dimethylaminopyridine (13 mg, 0.1 mmol) were added at room temperature and 
the resulting reaction mixture was stirred for 18 hours, checking periodically by 
TLC. The solution was washed thrice with a saturated solution of sodium 
carbonate and twice with a saturated solution of sodium chloride. The organic 
phase was then dried over sodium sulfate, filtered and the solvent was removed 
by evaporation under reduced pressure. The crude product was purified by 
gravimetric chromatography on silica gel column (petroleum ether/ethyl acetate 




fluorobenzoate (190 mg, 61%) as a white solid. 1H-NMR (CDCl3, 300MHz, 
298K) δ: 8.27-8.18 (m, 2H), 7.98-7.89 (m, 2H), 7.60-7.19 (m, 18H), 7.11 (t, 
2H, J=8.7Hz), 5.75-5.63 (m, 1H), 4.04-3.86 (m, 1H), 3.99 (d, 2H, J=14.1Hz), 
3.90 (d, 2H, J=13.1Hz), 3.67 (d, 2H, J=14.1Hz), 3.43 (d, 2H, J=13.4Hz), 3.49-
3.35 (m, 1H), 2.07-1.87 (m, 2H), 1.83-1.66 (m, 2H). 13C-NMR (CDCl3, 
75.4MHz, 298K) δ: 168.6 (C), 167.5 (C), 162.8 (d, C, JCF=211.8Hz), 140.4 (C), 
139.9 (C), 133.4 (d, CH, JCF=9.8Hz), 129.2 (CH), 128.6 (CH), 128.4 (CH), 
128.3 (CH), 127.1 (CH), 126.9 (CH), 116.4 (d, CH, JCF=21.9Hz), 75.2 (CH), 
62.0 (CH), 58.2 (CH), 55.4 (CH2), 54.4 (CH2), 28.4 (CH2), 18.0 (CH2). 
 
N,N,N’,N’-Tetrabenzyl-2,3-diaminocyclopent-1-yl Palmitate (7)  
N,N,N’,N’-Tetrabenzyl-2,3-diaminocyclo-pentan-1-ol 2 (250 mg, 0.525 mmol) 
was dissolved in dichloromethane (5 mL). Palmitoyl chloride (260 mg, 1.05 
mmol), triethylamine (290 µL, 160 mg, 2.1 mmol) and 4-
dimethylaminopyridine (13 mg, 0.1 mmol, 0.2 eq) were added at room 
temperature and the resulting reaction mixture was stirred for 3 hours, checking 
periodically by TLC. The solution was washed thrice with a saturated solution 
of sodium carbonate and twice with a saturated solution of sodium chloride. 
The organic phase was then dried over sodium sulfate, filtered and the solvent 
was removed by evaporation under reduced pressure. The crude product was 
purified by gravimetric chromatography on silica gel column (petroleum 
ether/ethyl acetate 98:2 as eluant) affording N,N,N’,N’-tetrabenzyl-2,3-
diaminocyclopent-1-yl palmitate (150 mg, 40%) as a white solid. 1H-NMR 
(CDCl3, 300MHz, 298K) δ: 7.42-7.18 (m, 20H), 5.39-5.29 (m, 1H), 3.87 (d, 
2H, J=14.1Hz), 3.78 (d, 2H, J=13.5Hz), 3.82-3.72 (m, 1H), 3.62 (d, 2H, 
J=14.1Hz), 3.39 (d, 2H, J=13.7Hz), 3.33-3.23 (m, 1H), 2.24-2.16 (m, 2H), 1.92-





N-Benzylated trans-1,2-Diaminocyclohexanes (8-10)  
trans-1,2-Diaminocyclohexane (1.0 g, 8.8 mmol) was dissolved in acetonitrile 
(10 mL). Benzyl bromide (6.0 g, 35 mmol) was added dropwise and the 
resulting solution was stirred at room temperature for 15 minutes. 
Triethylamine (4.4 g, 43.8 mmol) was added dropwise during a period of 15 
minutes and the resulting reaction mixture was stirred at room temperature 
overnight. The solvent was removed by evaporation under reduced pressure; the 
residue was paritioned thrice between diethyl ether and 2M HCl. The aqueous 
extracts were combined and sodium carbonate was carefully added until pH 9. 
The resulting solution was extracted thrice with dichloromethane. The organic 
extracts were combined, dried over sodium sulfate, filtered and the solvent was 
removed by evaporation under reduced pressure. The resulting mixture was 
separated by gravimetric chromatography on silica gel column (petroleum 
ether/ethyl acetate, 9:1→7:3 gradient), obtaining N,N,N’,N’-tetrabenzyl-trans-
1,2-diaminocyclohexane (3.08 g, 74%), N,N,N’-tribenzyl-trans-1,2-
diaminocyclohexane (130 mg, 4%) and N,N’-dibenzyl-trans-1,2-
diaminocyclohexane (330 mg, 13%).  
 
N,N,N’,N’-tetrabenzyl-trans-1,2-diaminocyclohexane 
1H-NMR (CDCl3, 300 MHz, 298K) δ: 7.47-7.40 (m, 8H), 7.31-7.19 (m, 12H), 
3.79 (d, 4H, J=13.8Hz), 3.37 (d, 4H, J=13.8Hz), 2.78-2.66 (m, 2H), 2.18-2.03 
(m, 2H), 1.78-1.65 (m, 2H), 1.20-0.99 (m, 4H). 13C-NMR (CDCl3, 75.4 MHz, 
298K) δ: 140.7 (C), 129.0 (CH), 128.1 (CH), 126.7 (CH), 58.3 (CH), 53.4 






1H-NMR (CDCl3, 300 MHz, 298K) δ: 7.42-7.18 (m, 15H), 3.87 (d, 2H, 
J=13.2Hz), 3.76 (d, 4H, J=13.8Hz), 3.55 (d, 2H, J=13.2Hz), 3.42 (d, 4H, 
J=13.8Hz), 2.96 (bs, 1H, exchange with D2O), 2.64-2.46 (m, 2H), 2.14 (d, 1H, 
J=12.6Hz), 2.02 (d, 1H, J=12.3Hz), 1.90-1.61 (m, 2H), 1.42-0.95 (m, 4H). 13C-
NMR (CDCl3, 75.4 MHz, 298K) δ: 141.1 (C), 140.1 (C), 128.8 (CH), 128.43 
(CH), 128.38 (CH), 128.28 (CH), 127.0 (CH), 126.8 (CH), 62.2 (CH), 58.0 
(CH), 53.9 (CH2), 51.7 (CH2), 32.0 (CH2), 25.8 (CH2), 24.8 (CH2), 22.8 (CH2).  
N,N’-dibenzyl-trans-1,2-diaminocyclohexane  
1H-NMR (CDCl3, 300 MHz, 298K) δ: 7.38-7.15 (m, 10H), 3.95 (d, 2H, 
J=13.5Hz), 3.49 (s, 2H, exchange with D2O), 3.34 (d, 2H, J=13.2Hz), 2.40-2.26 
(m, 2H), 2.02-1.70 (m, 4H), 1.40-1.17 (m, 4H). 13C-NMR (CDCl3, 75.4 MHz, 
298K) δ: 135.4 (C), 128.6 (CH), 128.3 (CH), 126.9 (CH), 69.4 (CH), 58.1 
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The research activity of the PhD project was centered on the design, preparation 
and preliminary evaluation of components of nanosized systems for Molecular 
Imaging applications, with a special focus on the development of MRI contrast 
agents. 
During the PhD period, different topics of this wide area of research were 
examined, three of them reaching full completion and being reported in this 
thesis. 
The first period was devoted to the design, preparation and testing of original 
amphiphilic Mn-based MRI contrast agents. Three novel EDTA-like chelating 
agents, bearing one or two long aliphatic chains placed on the ethylenediamine 
backbone were synthesized and the corresponding Mn(II)-chelates investigated 
by relaxometric techniques. The latter showed that the amphiphilic chelates 
easily forms supramolecular aggregates and are therefore useful for the 
preparation of lipid-based nanosystem such as micelles and liposomes. 
Moreover and quite surprisingly, the interaction of the amphiphilic complexes 
with human serum albumin led to the observation of a remarkable increase of 
the relaxivity, reaching values one order of magnitude higher than those 
observed with clinically used Gd-based CAs. This work allowed to demonstrate 
the possibility to use cheaper (and possibly safer) Mn(II)-chelates in place of 
the currently employed Gd(III)-chelates for this application, and that their 
efficiency may be comparable with their lanthanide couterpart, provided that 
suitable conditions (i.e.: the inclusion in a nanosized system) are adopted. 
The second activity involved the preparation of a unimolecular nanosized 
chelating agent, prepared by functionalization of polyethyleneimine with 




polynuclear nanosized complex, whose potential as MRI CA was evaluated 
through extensive relaxometric characterization. The Gd-polyethyleneimine-
phosphonate system shows a satisfactory thermodynamic stability, precluding 
an easy release of toxic Gd(III) ions in vivo, and is endowed with a relaxivity 
value well over 10 mM-1s-1. NMRD profiles evidenced the presence of metal 
ions with a low degree of hydration, largely compensated from a fast 
coordinated water exchange rate, a likely significant contributions from water 
molecule in the outer coordination sphere(s) and the slow tumbling rate of the 
nanometric polymeric molecule. Addition of a cationic surface modifier 
(meglumine), strongly improved the properties of the nanosized CA: the 
relaxivity raised due to the increase of the size and the hydration of the coated 
polymeric nanoparticle, and both solubility and thermodynamic stability of the 
system were enhanced as a consequence of the shielding effect of the 
hydrophilic cationic coating. 
Finally, during the routine periodical screening of the toxicity of the chelating 
agents and their synthetic precursor, a biological activity was noticed for a 
family of diamines used as synthons for the preparation of rigidified ligands for 
Mn(II). Investigation of this biological activity uncovered an unexpected block 
in the G1 phase of the cell cycle for some components of this family of 
diamines. This result shed a light on the importance of screening the toxicity of 
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